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VOORWOORD
Het is aft Bijna 10 jaar ben ik met dit proefschrift bczig gcwcest in een proces van
(weinig) hollen en (vcel) stilstaan. Toch ben ik trots en blij dat ik het afgemaakt heb.
Hicrbij hceft zekcr een gevoel van verplichting jegens de enorme inzct van anderen een
rol gcspceld.
Dit proefschrift is tot stand gekomen door nauwe samenwerking tussen de afdelingen
Gynaccologic van hct (voormalig) De Wevcr-Ziekcnhuis tc Heerlen en het Acadcmisch
Ziekenhuis te Maastricht en dc afdcling Endocrinologic en Voortplanting van dc Erasmus
Universiteit tc Rotterdam. Hct möge iedcrcen duidclijk zijn dat het schrijven van een
proefschrift allccn mogclijk is met dc hulp van vclcn. Zondcr anderen te kort te willen
doen, bedank ik toch cnkclc pcrsoncn met name: .;
* Hooggclccrdc Evers, Hans, bedankt dat je hct nooit opgegeven hebt. Bij hct inlc-
veren van een nicuw hoofdstuk lict jij elkc keer weer wctcn blij vcrrast te zijn en
kreeg ik hct mcestal per omgaandc perfect gccorrigccrd wcer terug. Jc kennis van
de Engclsc taal is overigens fenomcnaal.
* Hooggelcerdc Hcincman, Maas Jan, hct idee van dit proefschrift is van jou af-
komstig. Jij bent daarom ook de drijvcndc kracht achter dit ondcrzock gcwcest.
Jouw ceuwig cnthousiasme en optimisme heeft mij gcstimulcerd hct vol te hou-
den tot hct cindc. Huldc!
* Hooggelcerdc dc Jong, Frank, fantastisch hoc jij jc laboratorium beschikbaar hebt
gestcld voor mijn ondcrzock. Alles was altijd mogclijk! Daarnaast hebben je velc
corrccties en ideecn mij enorm gcholpcn. Toch blijf ik volhoudcn dat HST voor
Hormoon Substitutic Therapie Staat en nict voor Hogc Snclhcids Trcin.
* Zcergelecrdc Koudstaal, Johan en zccrgclccrdc Thcunisscn, Paul, bedankt voor
het zeer nauwkcurig bckijkcn en scorcn van dc velc coupes.
* Zeergcleerde de Lceuw, Rcnato, bedankt voor het beschikbaar stellen van jc la-
boratorium voor dc gonadotrofincn bcpalingcn en hct aandragen van idecen met
bctrekking tot hct rcccptor-onderzock.
* Zeergeleerde Grootenhuis, Arijan, alhoewcl we elkaar nog nooit ontmoct hebben
aarzclde je nict om mij tc hclpcn bij hct bewcrken van gegevens voor hct hoofd-
stuk over de reeeptoren. Bedankt!
* Mcvrouw Tolenaars, Gerda, het was heel aardig van je om buitcn kantoorurcn
matcriaal tc snijden en te kleurcn. Ik vond dczc scssies bcrc gczcllig.
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* Hooggclccrde lcdcn van de bcoordelingscommissie, bedankt voor de vlotte toet-
sing van het manuscript.
* (Zecr)gclccrdc (cx)lcdcn van dc Maatschap Gynaecologie en Verloskunde van
hct (tcgcnwoordig) Atrium Medisch Centrum te Heerlen/ Brunssum; J.E.M. De-
gcn, T.H.B. Salcmans, J.E.G.M. Stoot, J.H.M. Ubachs, J.A. Zandvoort, bedankt
voor hct gctoonde vertrouwen in mijn onderzoek en hct trouw aanmelden van gc-
schiktc paticnten.
* Licvc Marion, Eva en Gckc. Ik ben veel tc vaak voor jullie nict besehikbaar gc-
weest alhocwcl ik sterk de nciging heb dit tc bagatclliscrcn. De nu beschikbarc
tijd zal voor jullic zijn. Hct is absoluut waar Marion, dat hct bclachclijk is dat
icdcrccn hct badincrend heeft over "hct boekjc" maar dat dit boekje niets mcer of
minder is dan ccn levenswerk.
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CHAPTER 1
GENERAL INTRODUCTION
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The ovary is a dynamic organ. During a lifetime it undergoes many changes both
of function and morphology. Short term changes take place within one menstrual cycle,
long term changes occur in the course of the various episodes of life.
The li fctimc of an ovary starts during the embryonic stage of the female individual
-when germinal cells migrate to the gonadal folds- and progresses from early childhood
through the fertile years of life to the postmcnopausal period. Mcnarchc (first menstrual
bleeding) and menopause (last menstrual bleeding) arc critical markers in the lifetime
of ovarian function. Block (1) and Baker (2) have shown that after a s^ccp initial increase
of the number of oocytcs to 7,5 million by mitotic replication of primordial germ cells
and differentiation into oogonia, the number of oocytcs in the ovary sharply decreases
already during foetal life. At birth a girl will have around 2 million oocytcs left, by the
age of seven years, the number has been further reduced to 300,000.
The ovary and the dynamics of the ovarian cycle during fertile life have been
studied extensively. Much less is known about the ovarian changes after the menopause.
Morphology of the postmcnopausal ovary
In 1944, Hcrtig (3) described the changing nature of ovarian morphology and
argued that the aging of the ovary continues throughout life and is not completed at the
moment of menopause.
During the reproductive stage of life the volume of the ovary is largely determined
by the number and size of the antral follicles. With the menopause approaching, the
number of follicles sharply decreases. This is accompanied by a decrease in cortical
thickness. As a result, the gyrated aspect of the ovarian cortex becomes increasingly
more pronounced (4). As age advances, a growing number of corpora fibrosa and cor-
pora albicantia can be discerned in the ovary. Late in life, the remainder of these can still
be detected.
From a recent study (5) of the number of follicles in the ovaries it appeared that
the average number of primordial follicles in regularly menstruating, climacteric women
was ten times as high as among climacteric women already menstruating irregularly
(1392 ± 355 versus 142 ± 72). Virtually no follicles were found in postmcnopausal
women.
The size of the postmcnopausal ovary has been studied by Goswamy et al. (6). In
2246 women the volume of the postmenopausal ovary was examined using ultrasound
scans. It was established that the ovarian size diminishes with increasing postmcnopausal
age. Furthermore, the size of the postmcnopausal ovary was shown to be subject to
significant intcrindividual differences.
The size of the postmenopausal ovary is determined foremost by cortical thickness
and stromal volume. There is a distinction between the atrophic ovary on the one hand,
characterized by a thin cortex and scanty stroma, and the ovary with an increased stro-
mal volume on the other, referred to as stromal hyperplasia.
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Ovarian stromal (hyper)activity has been linked to the existence of endometrial
carcinoma since the early 30's (7). Later, also breast cancer was assumed to be related to
the stromal activity of the ovary (8). Woll and co-workers were the first to put forward
the hypothesis that the ovarian stroma produces steroids affecting the endometrium (9).
Histochemical investigations were performed to identify the presence of enzyme activity
necessary for the production of steroids in ovarian stroma (10,11). The extent of stromal
hyperplasia is probably correlated with the postmcnopausal ovarian steroid production
as recorded in the literature (12,13).
Function of the postmenopausal ovary
Postmenopausal oestrogen production results predominantly from the extra-
glandular conversion of androstenedione to ocstrone (14-16). This conversion takes
place mainly in fat tissue, so body weight is of prime importance in the oestrogen
production after the menopause (17,18).
Already in the sixties and seventies, studies were performed to find out whether
the postmcnopausal ovary still produces hormones and, if so, which hormones. The
results of these studies, however, contradict each other due to the use of different re-
search methods (Table 1). Some studies investigated peripheral (antccubital vein)
hormone levels, occasionally in combination with measurements prior to, during and
after oophorcctomy (19-23). Other studies focused on the peripheral and ovarian venous
hormone levels without considering the effect of oophorcctomy (24-28). Also, studies
have been performed measuring the plasma production rates of androgens and/or
ocstrogens, sometimes in combination with conversion rates and metabolic clearance
rates (15,29). Even in vitro studies using radioactive precursors have been used to
investigate the function of the postmenopausal ovary (30).
A number of studies has suggested that postmenopausal ovaries produce ocstrone
and oestradiol (25-27), yet most research has reached the conclusion that postmcnopausal
ovaries only produce a small amount of oestradiol (15,20-22,24,29,31) and that the
ocstradiol in the circulation is mainly generated through the peripheral conversion of
ocstronc and testosterone (32).
The views on androgen production by postmcnopausal ovaries arc virtually
unanimous. The production of both testosterone and androstenedione has been
documented (24,27,33). Some researchers regard testosterone as the quantitatively most
significant steroid produced by the postmenopausal ovary, a status others reserve for
androstenedione (25).
Several studies have looked into the factors determining the ovarian steroid
production by the postmenopausal ovary. Here again, however, the results arc conflicting.
In some studies an increase in ovarian steroid production was found after the
administration of hCG (21,34). A significant decrease in testosterone after administering
goserelin (a gonadotrophin releasing hormone [GnRH] agonist) to patients with breast
15
g* Table 1. Review of the literature concerning postmenopausal ovarian production of oestrone (E1). oestradioi (E2). androstenedione (A), and testosterone (T).
ovarian vs peripheral vein serum
levels
before vs after ooprx
(one group of uattenU)
before vs after oophorectomy
(dM. groups of patients)
in vitro studies
Mattmgly et al( 1969(30])
Raderetal(1973(19])
Juddetal(1974[24])
Juddetai(1974[20])
Greenblatt et al (1976 [25])
Vermeulan et al (1976 [26])
Judd etal(1976[22])
Dennefors et al (1980 [32])
Longcopeetal(1980[26])
Lucisano et 81(1984(27])
Aimanetal(1986[28])
E1=;E2=
EiT(P<0.05);E2t(P<0 05)
At(ns);Tt(P<0.01)
E2=
AT(ns);Tt(m)
E1=;E2t(s?)
A= ; Tf (s?)
Elf (P<0.01); E2t (PO.001)
At(P<0.01);Tt(P<0.001)
E1=;E2t(s?)
A= ; TT (S?)
A and T production
Ti 0X0.001): Ai (P4L001)
E1«;E2=
E1«; E2=
Ai(P<0.01);T4(P«.01)
I U - not signiHcant; s? - significance unknown
CBVMMi WntOIWCTKW
cancer was established by Dowsett et al. (33). In other studies steroid levels were found
to be unaffected by the administration of a GnRH agonist (35,36).
LH and FSH act on specific cells in the ovaries. LH stimulates theca and granulosa
cells, whereas FSH stimulates granulosa cells. LH and FSH consist of a common a -
subunit and a hormone specific ß-subunit both of which arc glycosylatcd (37). The ß-
subunit is the major determinant of the hormone specificity of receptor binding. The
hormones LH and FSH act on the gonads through binding to receptors located on the
surface of specific target cells, followed by activation of intracellular second messenger
systems and cellular responses (38). In the preovulatory phase of the menstrual cycle
LH stimulates ovarian theca cells, whereas FSH stimulates ovarian granulosa cells. (inRH
is released from the hypothalamus and binds to a specific receptor on the cell membrane
of the pituitary gonadotroph, resulting in stimulation of FSH and LH biosynthesis and
release (39). GnRH binding has also been reported in cxtrapituitary tissues, e.g. the
ovary (40,41). Binding sites and expression of receptor activity for LH, FSH, and GnRH
have been found in premenopausal human ovarian tissue (42-48). Little is known about
the presence of LH and FSH receptors in peri- and postmcnopausal ovaries (49-51). No
information is available on the expression and functional activity of GnRH receptors in
postmenopausal ovaries.
Objectives and approaches of this study
Although much has been written about medical problems in women caused by
their pcrimcnopausal state, for which hormone replacement therapy would be required,
data on the function of the postmenopausal ovary itself arc lacking. The aim of the
present study was to gain insight in the function of the postmcnopausal ovary and its
relationship with morphology.
The following questions served as starting points:
1. Does postmenopausal ovarian hormonal activity exist?
2. If so, to which degree is this activity related to ovarian morphology?
3. Do gonadotrophins still have a regulatory effect on this presumed postmcnopausal
ovarian activity?
4. Can gonadotrophin receptors be detected in the postmenopausal ovary?
In this study, postmcnopausal women were included, who for various reasons
underwent uni- or bilateral oophorcctomy with or without hysterectomy between 1
January 1990 and 1 January 1992 in the De Wever & Gregorius hospital in Hccrlcn, the
Netherlands. A study protocol was developed and approval was obtained from the Hospital
Ethics Committee to conduct the investigation. For the patients an informative brochure
was written (addendum 1), which included a form to give informed consent. The inclusion
criteria were as follows: no oestrogen replacement therapy for at least six months prior
to the investigation, last menstrual period at least twelve months before the start of the
study, and at least one ovary present at the time of surgery.
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This study was a collaborative project between the The Wever & Gregorius
Hospital, Hccrlen, Maastricht University Hospital, Maastricht, and the Erasmus
University, Rotterdam, The Netherlands.
Technical and scientific support was received from the Organon Research
Laboratories, Oss, The Netherlands. Financial support and supplementation of the GnRHa
triptorclin was received from Fcrring B.V., Haarlem, The Netherlands.
The results of this study arc presented in the next chapters:
In chapter 2 (section I), the method of ovarian vein blood sampling used in our
study will be described.
In chapter 2 (section II), the validity of our method of ovarian vein blood sampling
will be illustrated in a patient with a unilateral granulosa cell carcinoma of the ovary and
increased inhibin concentrations.
No studies have been published in which the effects of the administration of a
single depot-dose of a GnRHa to postmcnopausal women have been described. We will
report the effects on gonadotrophin release after the administration of a single depot-
dosc of a GnRHa to postmcnopausal women in chapter 3.
In chapter 4 (section I), the results will be presented of a study on the endocrine
activity of the postmenopausal ovary by measuring peripheral vein hormone levels before,
during, and after oophorcctomy together with measuring ovarian vein hormone levels
during operation. In order to determine whether gonadotrophins still have a regulatory
effect on this activity, the effects of pituitary down-regulation on these hormone levels
were studied as well.
In chapter 4 (section II), the effects of chronological age and time after menopause
on ovarian vein levels of T and A will be described. The group of patients which was not
treated with a GnRHa in chapter 4 (section I) was used for this study. The degree to
which ovarian activity is related to ovarian morphology will be investigated by studying
the relationship between ovarian production of individual hormones and the degree of
stromal hypcrplasia in the postmcnopausal ovary. The findings will be described in
chapter 5.
Since the activity of the postmcnopausal ovary appeared to be gonadotrophin-
dependent, the presence of gonadotrophin- and GnRH-reccptors in the postmenopausal
ovary was studied. The results of this investigation will be described in chapter 6.
The results of the presented investigations and the interrelationship of our findings
will be discussed in chapter 7. In this conclusive chapter the original questions pertaining
to postmenopausal ovarian function will be answered and suggestions for future re-
search will be done.
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Summary
A technique for the collection of utero-ovarian vein blood in postmcnopausal
women is described. This technique enables the study of the endocrinology of
postmcnopausal ovaries and of the pelvic endocrine milieu. The sampling of blood from
the utero-ovarian veins was almost always adequate, and there were no complications.
Introduction
Methods have been described for sampling ovarian venous blood during surgery
in laboratory animals (1) and in the human female (2). In the human, sampling is
particularly difficult outside the reproductive age range. Postmcnopausal ovaries are
small organs with a limited blood flow and a vulnerable vasculaturc. Literature on the
technique of blood collection in this special group is not available. Various attempts
were sought for circumventing the problems, and a suitable and practical method enabling
blood sampling from the ovarian outflow tract in most postmcnopausal women was
found.
Materials and methods
The aim of the present study was to develop a suitable sampling method to
study the relationship between function and morphology of the postmenopausal ovary.
In women who underwent a unilateral or bilateral salpingo-oophorcctomy with or with-
out a hysterectomy, utero-ovarian blood sampling was performed. The purpose of the
study was explained in detail to the participating patients, and informed consent was
obtained. Approval of the Institutional Review Board was obtained.
In a pilot study, ovarian vein sampling using a needle inserted in the ovarian
venous plexus was not successful. Suction via a syringe resulted in collapse of the vein
and thus obstruction of blood flow. The rate of blood collection by means of constant
suction was prohibitively low, and this technique interfered too much with the routine
operative procedures. Thus it was necessary to find an easier method for the collection
of blood from the utero-ovarian venous plexus. This was found in a simple blood-letting
technique that makes it possible to sample blood from the pelvic area after selective
clamping of the infundibulopclvic vessels.
Before the infundibulopclvic ligament is clamped, one must be certain that both
tube and ovary are freed from surrounding structures. If necessary, adhesions are removed.
The parietal peritoneum is gently opened, and the ovarian venous plexus, the ovarian
artery, and the ureter are identified. The infundibulopelvic ligament is clamped selectively,
and great care is taken to avoid the ureter. The ovarian venous plexus is bisected with a
fine pair of scissors, and the flow of blood from the utero-ovarian efferent vessels is
collected in a plastic cup (Fig. 1). This blood sample may be contaminated with a small
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mount of arterial blood from local artcrioles. After the collection of approximately 30
mL of blood, the proximal side of the ovarian venous plexus is clamped. The remainder
of the infundibulopelvic ligament can then be clamped, cut, and ligatcd. The procedure
is repeated on the contralatcral side to collect blood from the opposite ovary as well.
After the sampling of blood, surgery can be completed as indicated.
To allow estimation of the selectivity of the procedure, androstcnedionc (A)
levels were determined in the ovarian effluent thus obtained and compared with those in
a peripheral blood sample drawn at the beginning of the operative procedure shortly
before induction of anesthesia.
Both the central and peripheral blood samples were allowed to clot at room
temperature, centrifuged, and the supernatant stored at -20°C until assayed. The
measurement of hormones was described previously (3).
F/g. /. f/l/ {//««-ovarian vo.?cu/afu/r in /Ae /mman/ema/epe/v«. fBA t//m>-ovar/a/i ve//i Afoot/cW/ec//on
/n>m /Ae /n/und7/>u/o/>e/v/c //game«/ /'n
Thirty-eight women agreed to participate in this study. All were at least 1 year
postmcnopausal, and all were scheduled for surgery for clinical indications. Clinical
data on these patients are presented in Table 1. Statistical analysis was performed by the
paired nonparametric Wilcoxon's sign rank test.
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Age (y)
Time since menopause (y)
Indication for surgery
Endomctrial carcinoma
Endomctrial atypia
Endomctrial hypcrplasia
Lciomyoma uterus
CIN III
Benign ovarian cysts
Other indication
63.8 (53 to 81)
13.7(1 to 33)
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3
1
2
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Results
The initial study group consisted of 38 postmenopausal women. Sampling of
the utcro-ovarian venous plexus was not successful in 2 women. In one of them, obesity
was extreme and made it technically impossible to dissect the infundibulopclvic liga-
ment; in the other patient, adhesions around the left infundibulopclvic ligament were
too dense to sample this side appropriately.
In three patients, one ovary was missing because of previous gynecological
procedures; the contralatcral utcro-ovarian venous plexus in these individuals was
successfully sampled. Results of scrum A measurements in these patients' blood samples,
however, have not been included in the present study. Finally, in one patient the sampling
procedure was successful, but results of scrum A measurements were not included because
of laboratory problems. Sampling of the utero-ovarian venous plexus occurred without
complications; no perioperative hemorrhage occurred, and the postoperative recovery
was uneventful.
Results of scrum A measurements in peripheral blood samples and blood samples
from the right and left utero-ovarian venous plexus are presented in Table 2. In each
individual patient, except one, the scrum levels of A in the central compartment were
elevated above the peripheral one. The mean A levels in the right and left utero-ovarian
venous plexus were significantly higher than the mean A levels in the peripheral samples.
The scrum levels of A in the right utcro-ovarian venous plexus did not differ from those
in the left side.
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Scrum A levels'
ng/dL
Peripheral vein
Left ovarian plexus
Right ovarian plexus
153
349
367
±
±
±
106
214
215
(34 to 555)
(41 to 884)
(68 to 1,103)
[117]-'
[282]
[327]
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Discussion
This study is part of an investigation into the relationship between morphological
characteristics of postmcnopausal ovaries and their endocrine function. The endocrine
function of the ovaries is best evaluated by direct blood sampling at the time of
oophorcctomy and a technique of utcro-ovarian blood sampling had thus to be developed.
From the literature it was known that ovarian vein sampling could be helpful in
confirming the location of hormone-producing ovarian tumors (4). Percutaneous
transfcmoral venous blood sampling of the ovaries by way of cathctchzation has been
described, and appropriate imaging techniques have been developed for monitoring the
procedure (2). Direct utcro-ovarian blood collection in the baboon per laparoscopc has
been described (1). It is doubtful, however, whether this laparoscopic technique is
applicable in the human. The small dimensions of the postmcnopausal vessels in women
and the inherent risks of the procedure render it too perilous after the menopause.
In spite of many reports in the literature on intra-operativc ovarian vein blood
collection in women with virilizing tumors, an accurate description of the techniques
used is lacking. We only succeeded in tracing one study in which the authors gave a
brief description of their way of sampling the ovarian veins (5). These authors wrote
that the ovarian vein sample was obtained by cither aspirating the blood with a needle
and syringe or by dividing the vessel and collecting the blood in a small sterile glass
tube. They did not mention problems or complications associated with their way of
sampling. From their results, however, it became obvious that they could obtain only a
small amount of blood.
In our experience, insertion of a needle in the ovarian vein and suction by syringe
are likely to cause the vein to collapse. Only a limited volume of blood can be obtained
in this way, and the technique is very time-consuming, which interferes with the routine
operative procedures.
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The technique here presented allows for a sufficiently large volume of blood to
be obtained from the utcro-ovarian venous plexus within a few minutes. The technique
was adequate in 36 of 38 patients, and no complications were encountered.
The results of the A measurements show a significant elevation in the central
samples. Because A is a product of hormone synthesis in postmenopausal ovaries, these
results confirm the validity of the sampling method.
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In a patient with a granulosa cell tumour, stage 1 a 1, peripheral and ovarian vein
blood samples were drawn before, during and after bilateral oophorectomy. Before
operation inhibin and follicle-stimulating hormone levels were in the prcmcnopausal
range, whereas the peripheral level of ocstradiol and lutcinizing hormone were in the
normal postmcnopausal range. In the ovarian vein at the side of the tumour, inhibin and
ocstradiol levels were elevated, whereas in the contralatcral ovarian vein the concen-
trations of inhibin and ocstradiol were in the same range as in the peripheral vein.
Immunorcactivc inhibin levels in the homogenized tumour were 23 times higher than in
the contralatcral ovary, whereas inhibin bioactivitics in the same samples amounted to
126 and 14 U/mg protein, respectively. After removal of the tumour, peripheral scrum
follicle-stimulating hormone and inhibin levels were in the normal postmenopausal range
again. We conclude that inhibin can have a role as a marker for granulosa cell tumours.
Introduction
(iranulosa cell tumours arc hormone-producing ovarian stromal tumours. They
account for approximately 3% of ovarian neoplasms and for as much as 8% of ovarian
malignancies (1-3).
The diagnosis of granulosa cell tumour is usually made after laparotomy. Endo-
crinological studies with prc- and postoperative data arc not available.
The predominance of early stage tumours (90% stage 1 lesions) indicates the
low malignancy of granulosa cell tumours compared with most ovarian carcinomas.
However, Fox ct al. (4) stated that nearly 50% of women with granulosa cell tumours
will die from tumour-related events within 20 years from the moment of diagnosis. This
is likely to be caused by the high recurrence rate of more than 30% in the group with
stage 3 and 4 carcinomas and a mortality rate of 80% within 5 years in this group.
Women with stage lal granulosa cell carcinoma incur only a 8.9% risk of developing a
recurrence (2).
The sooner the granulosa cell tumour is detected, the better the prognosis will
be. The presence of a marker for granulosa cell tumours can improve the prognosis,
especially of recurrent disease. Ocstradiol is a well-known circulating marker for
granulosa cell tumours, but in one-third of cases the granulosa cell tumours are inactive
as far as steroid production is concerned and in patients with small granulosa cell rumours
the oestradiol levels in peripheral blood arc rarely elevated (1,5).
A recent report suggested the possibility of inhibin as a marker for granulosa
cell tumours (5): recurrences of granulosa cell tumours were related retrospectively to
changes in peripheral scrum inhibin levels.
In the present case report a patient is presented with a granulosa cell tumour in whom
we were able to obtain peripheral blood samples before, during and after oophorcctomy.
In addition, bilateral ovarian vein blood sampling was performed during surgery.
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A 48-year-old woman visited our Department because of painless vaginal
bloodloss. She had been postmenopausal for 18 months. At pelvic examination, the
right ovary was found to be slightly enlarged. A curettage was performed together with
a laparoscopy. During laparoscopy the right ovary appeared abnormal and enlarged with
a diameter of 4 cm. However, no laparotomy was performed because the patient had
requested to be informed about the laparoscopy findings first. Histological examination
of the tissue obtained at the curettage revealed endomctrium without mitotic figures,
comparable to that observed during the early prolifcrativc phase of the cycle.
Because of her participation in a project on gonadotrophin regulation in
postmenopausal women, the patient received an intramuscular injection of 3.75 mg
triptorclin (a gonadotrophin-relcasing hormone agonist) 14 days prior to laparotomy. A
peripheral venous blood sample was taken before the administration of triptorclin. One
day before oophorectomy and a few minutes before the start of the operation, repealed
peripheral venous blood samples were obtained. During surgery the right ovarian mass
was confirmed and a small amount of peritoneal fluid was observed and collected. Blood
was sampled from both ovarian veins. A right salpingo-oophorectomy was performed.
Direct histological examination revealed a granulosa cell tumour. Therefore, total
hysterectomy with salpingo-oophorcctomy of the remaining left side and omentectomy
were performed. Histological examination revealed that the well-differentiated granulosa
cell tumour was located in the right ovary only and confined within it. No tumour cells
were found in the peritoneal fluid. Consequently, the tumour was diagnosed as a stage
lal tumour. The endomctrium again showed signs of slight proliferation.
Six weeks after surgery, the patient visited the out-patient Department. She now
complained of hot flushes. Peripheral blood sampling was repeated.
Methods
Scrum hormone concentrations were measured in duplicate. All betwecn-assay
coefficients of variation were below 8%.
Serum LH and FSH were determined by luminescence assay with the Amcrlitc
LH-30 and FSH-60 kits (Amcrsham International, Amcrsham, UK). The results arc
expressed in terms of International Reference Preparations: 68/40 for LH and 78/549
for FSH. The detection limits were 0.12 U/L for LH and 0.5 U/L for FSH.
Serum ocstradiol and testosterone were measured by radio-immunoassay (Coat-
a-Count, Diagnostic Products, Los Angeles, CA). The detection limits were 0.03 nmol/
L for ocstradiol and 0.2 nmol/L for testosterone.
Serum ocstrone was measured after ether extraction by radioimmunoassay
(Biolab, Belgium). The detection limit for oestrone was 0.09 nmol/L.
Scrum inhibin levels were estimated by radioimmunoassay, using an antiscrum
against purified 32-kD bovine inhibin (No. 1989) and lodmatcd 32-kD bovine inhibin
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as tracer (6). These materials were obtained from Dr G Bialy, NIH Contraceptive
Development Branch Rockvillc, MD, USA. The standard used was a bovine follicular
fluid preparation with an arbitrary potency of 1 U of inhibin per ug protein. The Interna-
tional Research Standard for inhibin (86/690) has a relative specific activity of 60 ± 10
U/|ig (mean ± SEM, n=5) when expressed in terms of this bovine follicular fluid standard
(7). In the samples of the standard curve, pooled serum from postmenopausal women
was added; these sera were selected on the basis of undetectable inhibin levels in previous
assays. Inhibin concentrations in serum samples from 53 postmenopausal women
amounted to 0.67 ± 0.33 kU/L (mean ± SD; range 0-1.13 kU/L) when measured using
these materials, whereas levels in 8 prcmcnopausal women varied between 2.6 ± 0.30
(week 1 of the menstrual cycle) and 5.1 ± 0.55 (week 3 of the menstrual cycle) kU/L.
Parts of the tumour and left ovary were homogenized as described earlier for
Sertoli cell tumours (7). Immunoreactivity of inhibin was measured in these homogenates,
as well as inhibin bioactivity, using the suppression of FSH secretion from cultured rat
pituitary cells (7) as a response parameter.
Results
Peripheral and ovarian vein hormone levels are listed in Table 1.
7ä/>/<* /. //ormo/te /eve/5 »n /wipnera/ r'/V <"•</ ovarian f'ÖJJ venoi« serum*.
Day -14
Day-1
Day 0
Day +42
Months +4
Months +8
:P
:P
:P
L-O
R-O
P
:P
:P
Inhibin
(kU/L)
3.6
2.4
2.9
2.7
5.3
0.3
0.4
0.5
LH
(U/L)
23.3
9.3
10.6
11.5
9.5
45.0
FSH
(U/L)
5.9
4.9
5.1
4.7
4.4
>117.0
E,
(ntnol/L)
0.63
0.59
0.59
0.74
0.70
0.59
(nmol/L)
0.07
0.03
0.04
0.03
0.58
<0.03
Testosterone
(nmol/L)
0.4
0.1
0.3
1.5
0.5
0.3
*Dav 0 u //re </av o/opera/i'on. On </av - /< per/pnera/ ve/'n Mooa" was samp/ed" oe/bre Me a</m/nir/ra//on o/
//•ip/ow//ne. L an«/Ä mc/i'ca/e /e/J an«/ngn/ovary, nßspee/ive/y. £,•' oej/rone; f
Before the administration of triptorelin, the peripheral concentration of LH was
in the postmenopausal range. Surprisingly, the levels of FSH and inhibin were
prcmcnopausal. Ocstradiol, ocstronc and testosterone were in the postmenopausal range.
The day before surgery, the LH level was found to be decreased as a result of the admini-
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stration of triptorelin. On the other hand, the FSH level did not change and neither did
oestradiol, ocstronc or testosterone. No influence of triptorelin was observed on the
peripheral level of inhibin. The peripheral hormone levels during operation were not
different from those taken prior to surgery. No substantial differences were found be-
tween the peripheral hormone levels and the levels in the left ovarian vein. However, in
the right ovarian vein the levels of inhibin and oestradiol appeared to be higher than the
levels found in the left ovarian vein. No lcft-to-right differences were observed for the
other hormones.
Levels of immunoreactivc inhibin in the homogenates of the tumour and left
ovary were 59.6 and <0.7 U/mg protein, respectively, whereas inhibin bioactivities in
the same samples amounted to 126 and 14 U/mg protein, respectively.
Six weeks postopcrativcly, all hormone levels were in the normal postmcnopausal
range. At 4 and 8 months after surgery the inhibin scrum levels were still in the normal
postmcnopausal range and no clinical signs of recurrences were noted.
Discussion
Inhibin is a glycoprotcin, consisting of a hctcrodimcr of two subunits, u and ß,
linked by disulphidc bonds. The hormone surprcsscs the pituitary secretion of FSH
preferentially.
Inhibin is detectable in the circulation throughout the menstrual cycle in normal
women and is produced by the granulosa cells in the ovary, which explains the observed
rise in the late follicular phase in parallel with oestradiol (8). This is consistent with the
concept that both hormones are products of the maturing follicle. However, there is
doubt about the hypothesis that the selective suppression of FSH during the follicular
phase is due to inhibin from the dominant follicle, because Illingworth ct al. (9) found
no differences between inhibin levels in the ovarian veins draining the dominant ovary
and the contralatcral ovarian veins during the late follicular phase.
In the luteal phase, the levels of immunoreactivc inhibin continue to rise in
parallel with progesterone (10,11). This suggests that inhibin is also a secretory product
of the corpus lutcum, as was confirmed by the finding of higher ovarian vein levels of
inhibin at the side of the corpus lutcum compared to those at the contralatcral side (9),
and of immunoreactivc and bioactivc inhibin subunits in human corpora lutca (12,13).
Our patient entered a research program for which a number of blood samples
had to be taken. Because of this fortuitous circumstance, we were able to perform
endocrine measurements before and after the extirpation of the granulosa cell tumour.
The level of oestradiol in the right ovarian vein at the side of the tumour was
clearly elevated. In the left ovarian vein, the oestradiol level did not differ from the
peripheral blood level. Consequently, the increased oestradiol level in the right ovarian
vein was the result of the production of oestradiol by the tumour. However, the production
was apparently too low to increase the peripheral level of oestradiol above the normal
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postmenopausal level. This confirms previous reports that oestradiol is not an optimal
tumour marker for granulosa cell tumours, especially not in small tumours (5).
Although the peripheral oestrogen concentrations were in the normal postmeno-
pausal range, the endomctrium showed minimal signs of proliferation. No mitotic figures
were seen and the endomctrium was comparable with endometrium found in the early
prolifcrativc phase. As the scrum oestradiol level of the right ovarian vein was in the
range of the early prolifcrativc phase of the menstrual cycle, a local and circumscript
effect of oestradiol on endomctrium cannot be excluded.
No differences between peripheral and ovarian vein concentrations were seen
for LH, ocstronc or testosterone. The low peripheral FSH level, in contrast to postmeno-
pausal LH and oestradiol levels, suggests the presence of increased inhibin production.
The increased level of inhibin found in the ovarian vein at the side of the tumour, as well
as the high levels of immunorcactivc and bioactivc inhibin in the tumour tissue indicate
the granulosa cell tumour as the source of inhibin. The relatively high ratio of bio- over
immunorcactivity of inhibin in the tumour tissue suggests the presence of follistatin,
which is also produced by granulosa cells (14).
The markedly increased peripheral levels of inhibin show also that small
granulosa cell tumours arc able to produce detectable amounts of inhibin. Lappöhn et
al., in a retrospective analysis of serial measurements of scrum inhibin, demonstrated
that a rise of inhibin following extirpation of a granulosa cell tumour predicted recurrence
of the tumour months before the onset of clinical signs and symptoms (5).
Recently, Matzuk ct al. (15) showed that targeted deletion of the inhibin a-gene
in mice causes granulosa cell tumours in the homozygous offspring. These authors
suggested that inhibin can act as a gonad-specific tumour suppressor, and also indicated
that gonadal tumours might suffer from a relative decrease of expression of inhibin a-
subunit. In contrast, our data show that a granulosa cell tumour contains relatively high
levels of bioactivc inhibin, as is indicated also by the suppressed FSH levels in the
patient. This observation, together with the finding of high levels of bioactive inhibin in
dog Scrtoli cell tumours (7), makes the hypothesis of tumour suppression by a-inhibin
less likely.
We conclude that inhibin is a potential early marker for granulosa cell tumours.
This possibility remains to be tested by a study of an unselected series of patients. The
specific site of production of inhibin in our patient, i.e. the granulosa cell tumour, was
demonstrated; furthermore, detectable changes in peripheral serum inhibin levels were
present in the absence of an oestradiol increase in this postmenopausal patient with a
small granulosa cell tumour. It is likely that the FSH levels in our patient were decreased
because of the presence of inhibin. This confirms a role for inhibin in the modulation of
FSH secretion.
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Abstract , . , . . . . . .
Gonadotropin levels were determined in 17 postmcnopausal women before and
after administering a single depot-dose of the GnRH agonist triptorelin. E2 levels of all
samples were in the normal (low) postmcnopausal range and no differences were found
when the patients were grouped according to chronological age, or time after menopause.
Prc-GnRH agonist levels of LH and FSH were in the normal (high) postmenopausal
range. Two weeks after medication, LH and FSH had decreased to premenopausal le-
vels (P-'O.OOOl). Hight weeks after medication, LH levels were still low whereas FSH
levels had risen significantly again (P<0.0001). Both LH and FSH levels, however,
were still significantly below the scrum concentrations before the administration of
triptorelin (PO.0001). The prc-GnRH agonist level of FSH was significantly higher in
women > 67 years old (P<0.05), as compared to women < 67 years. Two weeks after
medication both LH and FSH levels were significantly higher in women more than 15
years after menopause (P<0.05), as compared to those <15 years. The same was found
for FSH in women > 67 years old. No further significant differences were noted. This
study demonstrates a significant decrease of LH and FSH serum levels in postmenopausal
women within two weeks after administration of a single depot-dose of the GnRH agonist
triptorelin. After eight weeks, in contrast to prcmcnopausal women, both LH and FSH,
although rising, were still significantly suppressed.
Introduction
Continuous or frequent intermittent administration of a GnRH agonist (GnRHa)
results in pituitary down-regulation. In a recent study (1), the effects have been studied
of a single depot-dose of the GnRHa triptorelin on serum levels of LH and FSH in the
early follicular and midlutcal phases of the menstrual cycle.
In postmenopausal women, no studies concerning the gonadotropin changes
following the administration of a single depot-dose of a GnRHa have been published so
far.
As part of a more extensive investigation into the relationship between morpho-
logical characteristics of postmcnopausal ovaries and their endocrine function, the GnRHa
triptorclin was administered. In the present study we report the effect of a single depot-
dose of the GnRHa triptorclin on pituitary and ovarian function in a group of 17
postmcnopausal women.
Patients and methods
The effect of a GnRHa was studied in 17 postmcnopausal women. Their age
ranged from 54-81 years (mean 66.9 years). Women were considered postmenopausal if
their last menstrual period was at least twelve months before the onset of the study. The
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range of the postmenopausal period was 1-29 years (mean 15.9 years). None of the
patients had had estrogen replacement therapy for at least six months preceeding the
investigation. The protocol used for this study was approved by the hospital ethics
committee. All patients signed an informed consent.
The active substance in Dccapcptyl is triptorelin (D-Trp*-LHRH) a synthetic
agonistic analogue of the naturally occurring GnRH. Dccapcptyl-CR (Ferring B.V.,
Haarlem, The Netherlands) contains 3.75 mg of triptorelin, dispersed in biodegradable
micro-capsules. The depot preparation is designed to release the agonist at an average
rate of 100 ug/day over a 30-day period (2).
Before the administration of the GnRHa, blood was drawn from an antccubital
vein. Further blood samples were obtained 2 and 8 weeks after the depot injection. All
blood samples were centrifuged at 3000 rcv/min for 10 min and the scrum was stored at
-20°C until assayed.
7bMe /. Äange am/ m«/ian £7 serum /eve/.v f/jmoMP in /7/jartmeno/wuW vvomen fa>/5wr #T2 /) .
2 (£2 2>, a/«/ * (£2 i> uwfa a//er /Ac ac/mmu/rarion o/a s/nfl/e atyxJ/-</a«' »/'/nr G>/J//a fri/Jftw/
c/ o /age a/i</ rime a/ter /as/ menjfrua/ p e n W fLA/P> on fne jremm /evei c^°£^ /.t «/.«o
17
Age
Age
LMP
LMP
menopausal women
Range
Median
< 67 years (n=9)
Range
Median
> 67 years (n=8)
Range
Median
<15years(n=9)
Range
Median
> 15 years (n=8)
Range
Median
E2 1
7-113
60.0
7-113
66.1
21-91
54.5
7-113
66.0
21-91
57.0
E2 2
5-143
50.0
5-143
60.0
22-78
49.0
5-143
45.0
22-78
53.0
E2 3
20-118
53.0
20-118
61.0
31-69
50.5
20-118
61.0
31-69
50.0
ra/wt fejf ^Wiicoxon/- w/fAm rowj. no jigm/fcwir «fiflenrnc« m meJianj
Afann-fFnitaey ( /- /«/: wi/Ain co/umnj/br age a/«/ /.A//^ no j/gni/icanr «/((Te/vnces /« me<//an.r wereyrwna'.
39
In all scrum samples, LH and FSH were assayed in duplicates using commercially
available immunofluoromctric assays (Delfia*, Pharmacia, Woerden, The Netherlands)
with IS 80/552 and IRP 78/549 as the respective standards. The detection limit of the
Dclfia hFSH and hLH assays is 0.05 U/L, if the limit of sensitivity is defined as two
standard deviations above the mean of '0 ' standard measurement values (mean value+ 2
S.D.). The intra- and interassay coefficients of variation were less than 7.5% for LH and
less than 5% for FSH. All samples from an individual woman were analyzed in the same
assay to eliminate interassay variation.
F.2 levels were measured using a RIA kit (Diagnostic Products Corp., Los Angeles,
CA). The intra- and interassay coefficients of variation were less than 15% and less than
19%, respectively.
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Age
Age
LMP
LMP
menupausal women
Range
Median
i 67 years (n=9)
Range
Median
> 67 years (n=8)
Range
Median
£ 15 years (n=9)
Range
Median
> 15 years (n=8)
Range
Median
LH1
11.0-40.8
26.8'->
11.0-40.8
26.5'-^
17.5-38.1
29.9'->
11.0-40.8
20.3'-
17.5-38.1
29.9''
LH2
2.8-11.8
5.7'
2.8-6.9
5.0'
4.5-11.8
6.7'
2.8-6.4
5.0'-'
4.5-11.8
6.9'*
LH3
0.05-20.1
6.P
0.1-20.1
7.2'
0.05-19.3
4.3>
0.1-16.9
3.9-
0.05-20.1
11.4^
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In order to investigate the effect of chronological age on the LH and FSH scrum
levels, the 17 postmcnopausal women were subdivided into two groups of 5 67 years
(n=9) and > 67 years (n=8), respectively, using the median as dividing point. Also, the
influence of time after menopause on scrum levels of LH and FSH was investigated by
dividing the postmcnopausal patients into two groups of < 15 years after the menopause
(n=9) and > 15 years after the menopause (n=8), with the median as dividing point.
,-,,y, Wilcoxon's signed rank test was used for the statistical analysis of differences in
LH and FSH serum levels between individual blood samples of all 17 postmcnopausal
women. The influence of chronological age and time after menopause on LH and FSH
scrum levels was studied by applying the Mann-Whitney U-tcst. t
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17 menopausal women
Range
Median
Age £ 67 years (n=9)
Range
Median
Age > 67 years (n=8)
Range
Median
LMP < 15 years (n=9)
Range
Median
LMP > 15 years (n=8)
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Median
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Results
During and after the administration of the GnRHa, no side effect of the drug was
noted. The E2 scrum levels before medication were in the normal postmenopausal range.
Two and eight weeks after the administration of the GnRHa, no differences in E2 scrum
levels were noted (Table 1). The scrum levels of LH and FSH before and after treatment
arc shown in Table 2 and 3 and Figures 1 and 2. The pre-GnRHa LH and FSH scrum
levels were in the normal postmenopausal range. Two weeks after the administration of
the GnRHa, the LH and FSH scrum levels were significantly suppressed (P<0.0001).
Eight weeks after the administration of the GnRHa, only the FSH serum level had in-
creased significantly again (P<0.0001). Both LH and FSH serum levels, however, were
still below the prc-GnRHa levels (P<0.0001). When evaluating the effect of chronological
age on the LH and FSH scrum levels, no statistical differences were found between the
E2 scrum levels of these two groups for all samples (Table 1). Scrum levels of LH and
FSH before and after the administration of the GnRHa in these groups arc shown in
Table 2 and 3. The prc-GnRHa levels of LH were not significantly different between
both groups. The prc-GnRHa levels of FSH in the older group, however, were significantly
higher (P* 0.05). Two weeks after the administration of the GnRHa, the LH scrum level
was the same in both groups. FSH, however, was significantly higher in the group of
olderpostmenopausal women (P<0.05). LH and FSH scrum levels eight weeks after the
administration of the GnRHa were the same in both groups.
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postmcnopausal women (P<0.05). LH and FSH scrum levels eight weeks after the
administration of the GnRHa were the same in both groups.
When evaluating the effect of time after menopause on the LH and FSH scrum
levels, again, no statistical differences were noted for the E2 scrum levels between both
groups for all samples (Table 1). Serum levels of LH and FSH before and after
administration of the GnRHa are shown in Table 2 and 3. Before treatment, both the LH
and FSH scrum levels were the same in both groups of patients. Two weeks after
administration of the GnRHa, however, both LH and FSH were significantly higher in
the group of patients >15 years after the menopause (P<0.05). Eight weeks after the
administration of the GnRHa, the LH and FSH serum levels were the same in both
groups.
Discussion
GnRHa has been used in premenopausa! patients for various indications. Little
information, however, is available on the administration of GnRHa in postmcnopausal
women. In postmcnopausal women, GnRHa has been used in studies investigating the
hormonal changes in the menopause (3,4), and in studies investigating the possible role
of LH in the etiology of hot flushes (5-7). GnRHa has also been used in phasc-2 studies
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of patients with advanced ovarian and breast carcinoma (8-14).
In all studies mentioned, GnRHa was administered either frequently or continuous-
ly. Hormonal data concerning discontinuation of a GnRHa are scarce, and the effect on
gonadotropins after the administration of a single depot-dose of GnRHa in postmeno-
pausal women has never been published before.
In the present study, a single depot-dose of triptorelin was given to 17 postmeno-
pausal women. E2 serum levels were in the normal postmenopausal range for all samples,
and no differences were found between groups when the patients were divided according
to chronological age and time after menopause. Therefore, possible influences of
differences in E2 scrum levels on the LH and FSH basal levels, as well as the response
of the pituitary to the GnRHa, or to endogenous LHRH during the recovery period
which follows down-regulation can be excluded. Two weeks after medication, LH and
FSH levels were reduced to < 25% of their initial scrum concentration. This reduction is
comparable with the cITcct of administration of a single depot-dose of triptorelin in
prcmcnopausal women during the early follicular and mid-luteal phase (1). Studies in
premcnopausal women have shown that LH and FSH arc back to prc-GnRHa levels
within 6 weeks after discontinuation of medication. In the study of Broekmans and co-
workers, this was seen for FSH levels, but normal levels of LH were only found 8 weeks
after administration of the GnRHa. In the present group of postmenopausal women 8
weeks after the administration of the single depot-dose, mean LH and FSH levels had
increased again but were still significantly below the initial prc-GnRHa levels. In nine
postmenopausal women, the LH scrum levels decreased further between 2-8 weeks
after administration of the GnRHa. This was found for FSH in only one patient. Three
patients had normal FSH again 8 weeks after the administration of the GnRHa (Fig. 2).
Two of these patients were older than 70 years. Their mean and median E2 levels for all
samples were not different from all other patients. The question arises whether the slow
recovery of LH and FSH is caused by a reduced release of hypothalamic GnRH, a
decreased sensitivity of the pituitary gonadotroph cells, a persisting depletion of gona-
dotroph cell membrane GnRH receptors, or a difference in the bio-availability of
triptorelin in postmenopausal women.
Few studies have been published describing gonadotropin secretion in the course
of the postmenopausc. After the onset of natural menopause, serum gonadotropin levels
rise progressively because of the decline in negative feedback by ovarian steroids and
inhibin. Several studies have noted secondary physiological decline in pituitary
gonadotropin hypcrsecrction with advancing chronological age and time after the
menopause (15-18). In the first decade after menopause, the LH and FSH serum levels
have been noted to decrease already. Very limited information, however, exists about
the precise mechanism of this neuroendocrine manifestation. It has been suggested that
the mechanism accounting for the reduction in pituitary gonadotropin release may con-
sist of both alterations in the episodic release pattern of hypothalamic GnRH and of
changes in the pituitary gonadotroph responsiveness (18). It has also been postulated
that ageing affects the secretory activity of cither the pituitary gonadotroph cells or the
GnRH neurons (17).
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Others have found no such age-related attenuation in gonadotropin release (19).
In the present study, patients < 67 years old had no higher serum prc-GnRHa serum
level of LH than patients > 67 years old. The scrum level of FSH was even significantly
higher in the group of patients > 67 years old (P<0.05). The effect, however, of the
administration of a single depot-dose of the GnRHa triptorelin on LH and FSH, as well
as the recovery, was the same in both groups. Dividing the patients according to time
interval from the last menstrual period, it appeared that, in contrast to other studies,
there was no significant difference in the prc-GnRHa levels of LH and FSH in either
group. The effect of a GnRHa in both groups was also the same.
From the present study we conclude that, in contrast to other studies, chronological
age and time after menopause have no significant effect on the basal activity of the
hypothalamus and the pituitary concerning gonadotropin production and release. We
found that 2 weeks after the administration of a single depot-dose of the GnRHa triptorelin
in postmcnopausal women, the scrum gonadotropin levels were suppressed to prcme-
nopausal levels. Eight weeks after the administration of the GnRHa the LH and FSH
scrum levels, although rising again, were still significantly lower than the initial levels.
This is in contrast with prcmenopausal women. E2 can be excluded as a determining
factor of this prolonged suppression, as can basic physiological activity of the
hypothalamus and the pituitary. One possible mechanism which may be held responsible
for the prolonged suppression is an attenuated replenishment of depleted pituitary cell
membrane GnRH receptors in postmcnopausal women.
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Abstract
The endocrine activity of the postmcnopausal ovary and the effect of pituitary
down-regulation were studied in a group of 35 postmenopausal women. All women
underwent oophorcctomy with or without hysterectomy. Fifteen women received a sin-
gle dose of a depot GnRH agonist (GnRHa) 2 weeks before operation, whereas 20 women
formed the control group. Peripheral venous levels of LH, FSH, cstrone, 17ß-estradiol,
testosterone (T), androstencdione (A), sex hormone-binding globulin, and dehydro-
cpiandrostcronc sulfatc were measured 2 weeks before, during, and 6 weeks after surgery.
Ovarian venous blood was sampled during surgery.
In the GnRHa and control groups, ovarian venous levels of A and T were
significantly higher, and those of dchydrocpiandrosterone sulfatc and sex hormone-bin-
ding globulin significantly lower, compared to the peripheral levels. A significant decrease
in T was found in the peripheral and ovarian vein samples during pituitary down-
regulation with GnRHa. Six weeks after operation, peripheral T levels were significantly
lower than those during surgery in the group that was down-regulated at the time of
oophorectomy.
We conclude that the postmcnopausal ovary produces significant amounts of A
and T, although only T contributes significantly to its peripheral scrum levels. T production
by the postmcnopausal ovary is in part stimulated by the high levels of circulating
gonadotropins, although pituitary down-regulation does not completely abolish andro-
genic activity.
Introduction
Early studies on the endocrine function of the postmenopausal ovary have shown
conflicting results (1-6). This may be the result of variation in patient population,
laboratory methods applied, and parameters investigated. Some studies have postulated
that high postmcnopausal gonadotropin concentrations stimulate ovarian androgen
production (4,7). No studies have been published to corroborate this suggestion.
Only a few recent papers have addressed the steroidogenic function of the
postmcnopausal ovary. Lucisano ct al. (8) concluded that the postmenopausal ovary
continues to produce androgens and can be a potential source of estrogens and proges-
terone. Dowsctt et al. (9) found a significant decrease in peripheral serum levels of 17ß-
cstradiol (E2), androstencdione (A), and especially testosterone (T) 4 weeks after the
administration of a GnRH agonist (GnRHa). Recently, the endocrine function of the
postmenopausal ovary was reviewed (10).
The aim of the present investigation was to study the effect of administration of a
depot GnRHa and oophorectomy on circulating hormone levels in postmenopausal
women and to determine the endocrine activity of the postmenopausal ovary by measuring
hormone levels in peripheral (antecubital vein) and ovarian venous blood.
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Subjects and methods « :« u
Ovarian function was investigated in 35 postmcnopausal women, who underwent
laparotomy for various gynecological disorders. All women had had their last menstrual
period more than 12 months before operation; none had received estrogen replacement
therapy for at least 6 months preceding the investigation. The clinical data arc summarized
in Table 1. The study was approved by the hospital ethics committee. All patients guvc
written informed consent. • i - > ; .-••.-.'.•
From all patients, blood was taken from a peripheral vein 2 weeks before surgMp
Subsequently, the patients were assigned altcmatingly to 1 of 2 groups. The control
group consisted of 20 patients who received no medication. The GnRHa group originally
also consisted of 20 patients who received a 3.75-mg im injection of the GnRHa triptorcltn
(Dccapcptyl-CR, D-Trp' GnRH in biodegradable micro-capsules, Fcrring, Haarlem, The
Netherlands).
ifA or
Ayj/twcfomy.
Control group
(n=20)
GnRHa group
(n-15)
Age (yr)
Yrs since menopause
Wt (kg)
Ht(m)
Body mass index (kg/m2)
Indication for surgery
Endometrial carcinoma
Endometrial atypia
Endocervical atypia
Leiomyoma uterus
Ovarian cyst
60.0
10.5
73.3
1.60
27.5
13
3
0
2
2
(52-81)
(1-32)
(52.0-107.5)
(1.47-1.74)
(20.1-42.5)
67.0(54-81)
15.0(1-29)
69.0(57.5-98.8)
1.60(1.56-1.69)
27.3(21.6-36.3)
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1
3
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Five patients had to be excluded from this group due to sampling problems (II),
inappropriate administration of GnRHa, and granulosa cell tumor of the ovary (12). A
significant decrease in scrum LH and FSH levels within 2 weeks after the single admini-
stration of the same depot GnRHa was noted in a previous study in postmcnopausal
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women (13). At the time of surgery, blood was again taken from a peripheral vein and
from the ovarian veins according to a method described previously (11). All patients
had macroscopically normal ovaries. Six weeks after operation, i.e. 8 weeks after
triptorclin administration, a final sample of peripheral blood was obtained. This time
was chosen because in prcmcnopausal women the peripheral serum gonadotropin levels
had returned to pretrcatment levels 8 weeks after the administration of a single 3.75-mg
depot-dose of triptorclin (14).
Blood samples were allowed to clot after collection. The collected serum was
stored at -20°C until assayed.
Scrum levels of LH, FSH, estrone (El), E2, A, T, sex hormone-binding globulin
(SHBG), and dchydrocpiandrostcrone sulfatc (DHEAS) were measured. LH and FSH
were assayed using an immunofluoromctric assay (Delfia, Pharmacia, Woerden, The
Netherlands) with IS 80/552 and IRP 78/549 as the respective standards. El and T were
measured by RIA, as described previously (15,16). E2, A, and DHEAS levels were
measured using RIA kits (Diagnostic Products Corp., Los Angeles, CA), and SHBG
was estimated using a two-site immunoradiomctric assay from the same supplier.
The detection limit, defined as the value that is 2 SD above the mean of zero
standard measurement values, of the Delfia human LH and human FSH assay was 0.05
U/L. The sensitivities of the other assays were: El, 20 pmol/L; E2, 4 pmol/L; A, 0.1
nmol/L; T, 0.2 nmol/L; SHBG, 1 nmol/L; and DHEAS, 0.5 umol/L.
lntra- and interassay coefficients of variation were both less than 7.5% for LH;
both less than 5% for FSH; less than 14% and 19%, respectively, for the El assay; less
than 15% and 19% for the E2 assay, respectively; less than 11% and 17% for the A
assay, respectively; less than 3% and 5% for the T assay, respectively; less than 4% and
5% for the SHBG assay, respectively; and less than 4% and 6% for the DHEAS assay,
respectively.
To exclude possible artifacts caused by mixing the ovarian venous blood with
other fluids, such as peritoneal fluid, during sampling, immunoglobulin M (IgM) levels
were estimated in the peripheral and ovarian veins, collected at the time of surgery, in
five patients. IgM is a relatively stable protein, which can be measured accurately and is
not metabolized by the ovary. IgM was measured using a single radial immunodiffusion
technique in an agarosc-gcl layer (LC-Partgcn IgM, Behringwerke, Marburg, Germany).
The assay was standardized against an in-house protein standard. The intra- and interassay
coefficients of variation were less than 15%.
On the assumption that the GnRHa and control groups would not show a normal
distribution of results, we performed non-parametric statistical testing. The Wilcoxon
matched pairs sign rank test was used for statistical analysis of differences in scrum
hormone levels between individual blood samplings. The Mann-Whitney U test was
used for statistical analysis of the influence of GnRHa administration on serum hormone
levels at various sampling moments.
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Results
The mean serum hormone levels at all sampling points arc summarized in Figs.
1-3. Because no normal distribution may be assumed, the median values and ranges of
all scrum hormone levels used for statistical analysis by nonparametric tests arc indicated
in the text.
In the GnRHa group, serum levels of LH and FSH (Fig. 1) were significantly
suppressed to premenopausal levels 2 weeks after the administration of a single depot-
dose of triptorclin [LH: median, 5.7 IU/L (range, 2.8-11.8) vs. 26.6 IU/L (range, 11\0-
40.8); FSH: 7.4 IU/L (range, 2.6-12.5] vs. 54.5 IU/L (range, 26.5-91.9)).
No significant differences were noted between the left and right ovarian venous
levels of El , E2, A, T, SHBG, and DHEAS. Therefore, the mean of these two
concentrations for each patient was used for further calculations. If blood was obtained
from only one ovarian vein, the value for this sample was used.
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Control group
Hormone levels in the peripheral serum sample taken 2 weeks before surgery
were not different from those collected at the time of surgery (Fig. 2). Six weeks after
operation, peripheral venous levels of El, E2, and T were significantly lower than those
before operation [FJ: 147 pmol/L (range, 3-300) vs. 180 pmol/L (range, 10-405); E2:
58 pmol/L (range, 11 -151) vs. 62 pmol/L (range, 26-195); T: 1.0 nmol/L (range, 0.5-3.4)
vs. 1.6 nmol/L (range, 0.8-7.7)].
In five patients, IgM levels were measured in peripheral and ovarian venous blood,
obtained at the time of surgery. No significant differences were found [ovarian vein: 1.1
g/L (range, 0.3-1.7); peripheral vein: 1.2 g/L (range, 0.4-2.1)].
No peripheral-ovarian venous concentration differences were found for El and
E2 (Fig. 3). The ovarian venous levels of A and T were higher than the peripheral venous
levels obtained at the time of surgery [A: 11.7 nmol/L (range, 3.8-31.2) vs. 5.4 nmol/L
(range, 2.1 -19.4); T: 3.3 nmol/L (range, 1.3-41.1) vs. 1.8 nmol/L (range, 0.8-4.1)]. The
levels of SHBG and DHEAS were lower in the ovarian vein than in the peripheral vein
during surgery [SHBG: 39.6 nmol/L (range, 13.6-77.3) vs. 44.0 nmol/L (range, 15.8-
97.6); DHEAS: 2.5 umol/L (range, 0.3-10.4) vs. 3.5 umol/L (range, 0.5-13.4)].
(inRHa yroup
The peripheral venous T level (Fig. 2) was reduced at the time of surgery compared
with the level in the peripheral vein before the administration of GnRHa [ 1.4 nmol/L
(range, 0.6-1.9) vs. 1.5 nmol/L (range, 0.6-3.0)]. Peripheral venous levels of El, E2, A,
SHBG, and DHEAS were not influenced by pituitary down-regulation. Six weeks after
operation, the peripheral venous T level was decreased even further compared to that
during operation [1.0 nmol/L (range, 0.5-1.7) vs. 1.4 nmol/L (range, 0.6-1.9)].
The ovarian venous levels of A and T were higher than the peripheral venous
levels during operation [A: 10.8 nmol/L (range, 3.0-24.6) vs. 4.5 nmol/L (range, 2.0-
8.0); T: 2.1 nmol/L (range, 0.7-6.6) vs. 1.4 nmol/L (range, 0.6-1.9)]. The ovarian venous
levels of SHBG and DHEAS were lower than the peripheral venous levels during opera-
tion [SHBG: 55.8 nmol/L (range, 20.0-110.8) vs. 64.8 nmol/L (range, 25.7-127.2);
DHEAS: 2.4 umol/L (range, 1.1-6.4) vs. 3.2 umol/L (range, 1.3-8.9)].
The effect of pituitary down-regulation on endocrine function was also studied
by comparing hormone levels in the control and GnRHa groups at the same sampling
times (Fig. 3).
For T, the peripheral and ovarian venous serum levels were lower in the GnRHa
group than in the control group at the time of surgery [peripheral vein: 1.4 nmol/L
(range, 0.6-1.9) vs. 1.8 nmol/L (range, 0.8-4.1); ovarian vein: 2.1 nmol/L (range, 0.7-
6.6) vs. 3.3 nmol/L (range, 1.3-41.1)]. The peripheral and ovarian venous scrum levels
of SHBG during operation were higher in the GnRHa group than in the control group
[peripheral vein: 64.8 nmol/L (range, 25.7-127.2) vs. 44.0 nmol/L (range, 15.8-97.6);
ovarian vein: 55.8 nmol/L (range, 20.0-110.8) vs. 39.6 nmol/L (range, 13.6-77.3)]. No
further significant differences were found.
52
! •
r'
A B C
control
A B C
OtiAHa-treatad
A B C
oontrol
F/g. 2 A/ean /w//>Aera/ .verum /eve/j f± S.E.A/J o/jte/To/«/* onrf 5//ÄC /n ro/ifro/
2 »veeAj fte/bne iu/ytrv ^4/ a/ fAe //me q^ju^pery ^B/ an</ 6 wt-etv a/?er
Discussion
Many studies have been performed to determine the endocrine function of
postmenopausal ovaries. The results of these studies, however, arc conflicting.
Early studies demonstrated the steroidogenic potential of the postmenopausal
ovary. The presence of steroid-specific enzymes in ovarian stromal tissue was demon-
strated by enzyme histochemical techniques (7,17,18). In vitro incubation studies
demonstrated the ability of postmenopausal ovaries to convert various precursor steroids
to androgens and indicated that the principal steroid produced is A, in addition to smal-
ler quantities of T and DHEA (1,19,20). In these studies, no signs of aromatizing enzyme
activity were found. Dennefors et al. (21), however, found aromatase activity in ovarian
stromal tissue and showed that the postmenopausal ovary can produce substantial amounts
of El in vitro.
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In many studies, peripheral and/or ovarian venous hormone levels were measured
with or without oophorcctomy. Although some studies found that T was the major
androgen secreted by the postmenopausal ovary (2-5,9), other researchers did not observe
any decrease in peripheral levels of T after oophorcctomy (22,23). In all of these stu-
dies, except that by Loncopc et al. (5), it was found that smaller amounts of A were
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produced as well. In contrast, Greenblatt et al. (6) concluded that A was the principal
androgen produced by the postmenopausal ovary. Some studies found substantial
production of El and E2 by the postmenopausal ovary (5,6,8.24,25). However, most
studies found no or only minimal E2 production by the postmenopausal ovary (2,4,21,26-
29), whereas most of the scrum level of El appeared to be derived from the peripheral
aromatization of A that occurs preferentially in fat and muscle tissue (26,30-33). It is
now generally accepted that circulating E2 in postmenopausal women is derived from
peripheral conversion of E1 and T, and the postmenopausal ovary and adrenal glands do
not contribute directly to the plasma E2 level (32).
In this study we investigated the steroid production of postmenopausal ovaries
by comparing the effects of GnRHa and oophorectomy on peripheral and ovarian venous
hormone levels. A comparison of the peripheral and ovarian venous steroid levels in the
GnRHa and control groups showed that the postmenopausal ovary produces T and A in
considerable amounts. Six weeks after operation, the peripheral scrum level of T was
significantly lower than the preopcrativc scrum level. This indicates that the steroid
production of T by the postmenopausal ovary contributes to the peripheral level. T may
be used as a substrate for the production of E2 by peripheral aromatization. In the control
group, the peripheral scrum level of E2 (and El) was significantly lower after operation.
In the GnRHa women, however, the difference between El and E2 scrum levels before
and after operation were similar, but did not reach significance.
In both the GnRHa and control groups, the ovarian venous SHBG and DIIP'AS
levels were significantly lower than the peripheral venous levels of these compounds. A
sampling error was excluded as a reason for this observation, because no peripheral-
ovarian gradient for IgM could be established. Because of differences in orders of
magnitude (DHEAS circulates in micromolc quantities), a contribution of DHEAS to
the production of other ovarian steroids is difficult to investigate. Utilization of SHBG
by the prostate (34) and endomctrium (35) has been described in recent publications.
We have to consider that the ovarian veins not only drain the ovary, but also
collect part of the venous effluent from the uterus. It remains to be elucidated whether
DHEAS is metabolized by pelvic tissues, e.g. endometrium. In our study the peripheral
and ovarian venous serum levels of SHBG were higher in the GnRHa group than in the
control group at all sampling moments. The reason for this difference remains unclear.
Many researchers have suggested that steroid production in the postmenopausal
ovaries is stimulated by the high endogenous gonadotropin levels. Some authors found
increased peripheral steroid levels after stimulation of postmenopausal women with
hCG (4,7). Dowsett et al. (9) found a significant decrease in T after the administration of
a GnRHa. In their study, only peripheral venous scrum hormone levels were inves-
tigated in patients with advanced breast cancer. Others, however, found no changes in
serum steroid levels after the administration of a GnRHa (36,37). The effect of GnRHa
on T production in this study, measured in both peripheral and ovarian veins, illustrates
that the postmenopausal ovary is influenced by gonadotropins. For A, no such effect
was found, probably because of the relatively large adrenal contribution to circulating A
levels.
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;.:,. In conclusion, 1) the postmcnopausal ovary produces significant amounts of A
and T, although only T contributes significantly to its peripheral serum levels; and, 2) T
production by the postmcnopausal ovary is in part stimulated by the high levels of
circulating gonadotropins, although pituitary down-regulation docs not completely
abolish androgcnic activity.
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Abstract
In 20 postmenopausal women the effects of chronological age and time after
menopause (postmenopausal age) on ovarian vein androgen levels were studied.
During oophorcctomy, ovarian vein hormone levels of testosterone (T) and andros-
tencdione (A) were measured.
The median for chronological age was 60 years and for postmenopausal age 10
years. For both chronological age and postmenopausal age, no significant relation with
ovarian vein levels of A and T were found.
We were not able to demonstrate a relation between pelvic A and T levels with
cither chronological or postmenopausal age.
Introduction
Many studies have been published regarding the endocrine function of the
postmenopausal ovary (1 -6). Recently we studied the effect of pituitary down-regulation
and oophorcctomy on the endocrine activity of the postmenopausal ovary in a group of
35 poslmenopausal women (7). From Ihis study we concluded that the postmenopausal
ovary produces significant amounts of A and T, although only T contributes significantly
to its peripheral scrum levels.
Little is known about the influence of ageing after the menopause on the endocrine
function of the postmenopausal ovary. In the studies at present available, serum hormone
levels were only measured in peripheral vein blood. From a previous study we know
that to determine the hormone secretion of an ovary, it is important to measure serum
hormone levels in ovarian vein blood (8).
The aim of the present investigation was to study the relation of chronological
age and postmenopausal age with the ovarian vein blood levels of A and T.
Patients and methods
Twenty postmenopausal women, who underwent laparotomy for various gyneco-
logic disorders, were investigated. All women had their last menstrual period more than
twelve months prior to operation. None of the patients had received estrogen replacement
therapy for at least six months preceding the investigation. The clinical data are
summerized in Table 1. The study was approved by the hospital ethics committee. All
patients gave a written informed consent.
During oophorcctomy, from all patients ovarian vein blood was obtained according
to a method described previously (8). Bloodsamplcs were allowed to clot after collection.
The collected serum was stored at -20°C until hormone estimations.
Serum levels of androstenedione (A) and testosterone (T), were measured as
described previously ([9,10]) Diagnostic Products Corp. Los Angeles,CA). The sensi-
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tivities of the assays were: A, 0.1 nmol/L; T, 0.2 nmol/L.
Intra- and interassay coefficients of variation were both less than 11% and 17%
respectively for the A assay, and less than 3% and 5% respectively for the T assay.
The effect of chronological and postmcnopausal age on serum hormone levels
was studied by dividing the patients into two groups with the median as dividing point.
The Mann-Whitney U test was used to evaluate the influence of chronological
and postmenopausal age on the peripheral and ovarian vein scrum hormone levels in
both groups.
oopAorectomy vw'/A or tWMour Ays/erec/omy.
Age (years)
mean : 62.9 (52-81)
median : 60.0
Years since menopause
mean : 12.5 (1-32)
median : 10.0
Indication for surgery:
Endomctrial carcinoma : 13
Endometrial atypia : 3
Leiomyoma : 2
Benign ovarian cysts : 1
Miscellaneous : 1
Results
For chronological age the median was 60.0 years and for postmcnopausal age
10.0 years. No significant differences were noted between the left and right ovarian vein
levels of all hormones studied. Therefore, the mean of these two concentrations for each
patient was used for further calculations. If only one ovarian vein was sampled, the
value for this sample was used. The effects of chronological and postmenopausal age on
the serum hormone levels in peripheral and ovarian vein blood have been described in
Table 2 and 3.
For both chronological age and postmenopausal age, no significant differences
were found for serum levels of A and T.
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Discussion
We studied the effect of chronological age and postmenopausal age on the ovarian
vein serum levels of A and T, because in a previous study of 35 postmenopausal women,
it was found that the postmenopausal ovary produces significant amounts of A and T
(7).
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Till now, only a few studies have been published on the relation between
chronological age and postmcnopausal age on circulating steroids levels and their regu-
lation mechanisms in postmcnopausal women. In these studies, only peripheral vein
serum levels of A and T were measured. It is known, however, that measuring hormone
serum levels in the ovarian vein is the most accurate way to detennine the secretion of
ovarian hormones.
Kwekkeboom and coworkcrs showed in 680 normal postmcnopausal women that
serum levels of LH and FSH decreased with age (9). They suggested a direct effect of
ageing on gonadotroph cells or an effect of age on the hypothalamic regulation of these
cells. Rossmanith and coworkcrs suggested that the mechanism accounting for the
reduction in pituitary gonadotrophin release is the reduced release of hypothalamic (JnRH
and of changes in the pituitary gonadotroph responsiveness (11,12). Other studies,
however, found no effect of postmcnopausal age on the basal activity of the hypothalamus
and/or the pituitary concerning gonadotrophin production and release (13,14). Alexander
and coworkcrs found no age related effect on hypothalamic GnRH secretory function
and release of pituitary gonadotrophins, but a primary age-related change in the ovary
(15).
For El and E2 it was found that chronological age or postmcnopausal age had no
significant influence on the serum levels (2,16-19). Chakravarti and coworkcrs (17)
showed that in the late postmcnopausal women the scrum levels of E2 had a tendency to
increase, whereas Vcrmculcn and coworkcrs (18) noted the opposite. Badawy and
coworkcrs, found a highly significant inverse correlation between postmcnopausal age
and El and E2 serum levels (20).
A positive relationship between SHBG and age has been described (2,21). Others,
however, found no relationship between SHBG with age in postmcnopausal women
although the group of patients studied was smaller (22).
Meldrum et al. found a significant decline for DHEAS in older postmcnopausal
women (19).
Chakravarti et al. found in the late postmenopausal women a lower concentration
of A and a higher concentration for T compared with prcmcnopausal levels (17). No
relevant differences for A and T were noted in the study of the effect of ageing on
circulating steroid levels of Mcldrum et al. (19).
In our study no relevant differences for A and T with chronological age and
postmenopausal age were noted. Therefore, we conclude that chronological age and
postmcnopausal age has no clear effect on the production of A and T by the post-
mcnopausal ovary. We realize, however, that the present study has some limitations.
The number of patients (n=20) studied is small and the age range (52-81 yrs) is large.
The endocrine parameters (A and T) demonstrate a wide range as well. In order to study
the relation between chronological age and postmcnopausal age with ovarian steroid
production a much larger study group is required and probably more specific endocrine
parameters (local steroid production) should be determined.
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Abstract
Objective: To study the relationship between ovarian production of estrone (El),
cstradiol (E2), testosterone (T), and androstencdione (A) and the ovarian degree of stromal
hypcrplasia in postmcnopausal women.
Design: In 18 postmcnopausal women, the ovarian vein hormone levels of El,
E2, T, and A were compared with the degree of ovarian stromal hypcrplasia. The degree
of stromal hypcrplasia was assessed by histological analysis (group 1: atrophic ovaries,
n=8; group 2: slight stromal hypcrplasia, n=8; group 3: moderate or severe stromal
hypcrplasia, n=2).
Results: The ovarian levels of El and E2 did not correlate with the ovarian degree
of stromal hypcrplasia. The ovarian levels of A in group 3 were significantly higher than
those in groups I and 2 (P-'0.02 and P<0.01, respectively). The ovarian levels of T in
group 3 were significantly higher than those in group 1 (P<0.01) but did not differ
significantly from those in group 2.
Conclusions: The amount of stromal hypcrplasia in postmcnopausal ovaries is
correlated with the ovarian vein levels of A and T. Morphological characteristics of the
postmcnopausal ovary determine the local (pelvic) endocrine status and may play a role
in the etiology of hormone-dependent diseases of the internal genitals.
Introduction
The ovary is an organ that exhibits considerable morphological and functional
changes from the embryonic stage in life until the postmenopausal period. Much is
known about these changes, especially in the reproductive period of life. Less is known
about the postmcnopausal state of the ovary. In a previous study, we concluded that the
postmenopausal ovary only produces significant amounts of androstcnedione (A) and
testosterone (T) and is still partly under pituitary control (1). In the present study, we
investigated the relationship between the morphological state of the postmenopausal
ovary and the endocrine function, with special emphasis on the production of A and T.
Patients and methods
Eighteen postmenopausal women (all participants in a previous study [1]), who
underwent laparotomy for different gynecological disorders were included in the study.
The clinical data arc summarized in Table 1. All women had their last menstrual period
more than 12 months before surgery; none had received estrogen replacement therapy
for at least 6 months before the investigation. The study was approved by the Hospital
Ethics Committee. All patients gave written informed consent.
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Age (year)
Years since menopause
Weight (kg)
Height (m)
Body mass index (kg/m-)
Indication for surgery
Endometrial carcinoma
Endomctrial atypia
Cervical atypia
Uterine lciomyoma
Benign ovarian cyst
12
3
1
1
1
63.1
12.4
72.7
1.59
28.8
(52-81)
(1-32)
(52.0-107.5)
(1.47-1.70)
(20.1-42.5)
Wumm'ffl/ </ato are S/IOW/I as meaVa/w, w/'/A Me ra/tge I'/I pa/wif Aeses.
At the time of surgery, blood was taken from the ovarian veins according to a
method described previously (2). Blood samples were allowed to clot after collection.
The collected scrum was stored at -20°C until assayed. Scrum levels of cstronc (F.1) and
T were measured by radio-immunoassay (RIA), as described previously (3,4). Estradiol
(E2) and A were measured with RIA kits (Diagnostic Products Corp., Los Angeles,
CA). The sensitivities of the assays were 20 pmol/L (El), 4 pmol/L (E2), 0.2 nmol/L
(T), and 0.1 nmol/L (A).
Intra- and interassay coefficients of variation were less than 14% and 19%,
respectively, for the El assay; less than 15% and 19% for the E2 assay, respectively;
less than 3% and 5%, for the T assay, respectively; and less than 11 % and 17% for the A
assay, respectively.
After removal, the ovaries of the 18 postmenopausal women were fixated in
buffered formaline, and transverse sections of the whole ovaries were made. A
representative section of each ovary was classified after staining with hematoxylin and
eosin into one of three groups according to the degree ofstromal hyperplasia: an atrophic
ovary is defined as an ovary with a maximum ovarian cortex width of 1 mm (Fig. 1),
slight stromal hyperplasia is defined as an ovary with a cortex wider than 1 mm (Fig. 2),
and moderate or severe stromal hyperplasia is defined as an ovary with a cortex wider
than 1 mm with cellular cortical stroma present in the medulla (Fig. 3). Three investigators
(M.J.H., J.K., P.H.M.H.T.) classified the ovaries independently, all unaware of the
endocrine data from any one patient. In 13 patients, the 3 individual scores were identical.
In 5 patients, consensus was attained on histological arguments.
For statistical analysis one-way analysis of variance was used.
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n
El
E2
(pmol/L)
Mean (±SEM)
Median
Range
(pmol/L)
Mean (±SEM)
Median
Range
Atrophie
8
184 ±79
206
44-258
81 ±36
88
11-126
Slight stromal
hypcrplasia
8
168 ± 76
166
64-285
115 ± 127
76
30-419
Moderate-severe
hypcrplasia
2
300 ±49
300
265 - 334
120±16
120
109- 131
One-way ana/wu o/variance,
«/egree o/j/roma/ «vper/>/a5/a.
aT^erencef M>ere/oun</ fteftveen £ / ana" £2 ant/ Me ovarian
Results
No significant differences were noted between the left and right ovarian vein
levels of El, E2, A, and T. Therefore, the mean of these two concentrations for each
patient was used for further calculations. If only one ovarian vein was sampled, the
value for this sample was used.
The number of patients in each group and the mean, median, and range of ovarian
vein scrum hormone levels of E1, E2, T, and A have been summarized in Tables 2 and 3.
The ovarian vein levels of El and E2 were not correlated with the ovarian degree
of stromal hypcrplasia. The ovarian vein level of T in group 3 was significantly higher
than that in group 1 (P<0.01) but did not differ significantly from the level of T in group
2. The ovarian vein level of A was significantly higher in group 3 than in groups 1 and 2
(P<0.02 and P<0.01, respectively).
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wi/A ovaries c/avj///et/ according /o /Ac t/egree 0/5/roma/ Av^e'p/a.f/a.
Atrophie Slight stromal Moderate-severe
hyperplasia hyperplasia
8 8
T (nmol/L) 3.011.1
Median 2.9*
Range 1.3 - 4.4
A (nmol/L)
Mcan(lSnM) 12.715.6
Median 11.6"
Range 3.8 - 22.4
nna/y.m o/'iwia/icc.' a .(igni/ican/ a7/7ereflce was/buna" ieftvee« /Ae ovanan vein /eve/sybr 7" in
M / ant/ 3 fa: P< 0.fl/). 77ie ovarian vein /eve/j o//( in group i were 5i'gn///can//v /i/gAer /Aa« /Aoje m
/ (7>. P<fl.O2; ana* in group 2 (c. P<0.»//
8.2113.4
3.2
1.7-41.1
11.214.7
10.8'
4.8 - 19.4
9.11
9.1
6.6-
27.41
27.4
23.7-
3.5
a
11.5
5.3
b.c
31.2
Discussion
The ovary is a dynamic organ in which the process of aging takes place in an
orderly and progressive way. During the reproductive period, the size and weight of the
ovaries vary considerably, depending predominantly on the follicular content. With time,
there is a gradual loss of ova and a progressive thinning of the ovarian cortex that becomes
increasingly wrinkled and gyrated. Small white scars (corpora albicantia) are typically
present in the thickened cortex. The vessels of the hilum and medulla become progres-
sively sclcroscd (5). All these changes result in a decrease in ovarian size after menopause.
The size of the postmcnopausal ovaries differs widely (6), caused in part by the
ovarian stromal cells. At one extreme, there is stromal atrophy. At the other extreme,
there is marked stromal proliferation appearing as stromal hyperplasia (7).
More than 50 years ago, the relation between ovarian stromal activity (e.g.,
hyperplasia) and cndometrial cancer was first indicated by Smith (8) and this relationship
was established subsequently for breast cancer (9). Hcrtig stated that endometrial activity
is correlated with the activity in the ovarian cortex (10). Woll et al. were the first to
suggest that steroids arc produced by cells localized in the ovarian stroma (11). Many
cndocrinological studies of postmcnopausal ovarian function followed, but the findings
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were conflicting (12-18). Dowsett et al. found that the ovarian production of steroids
could be suppressed by the administration of a gonadotropin-rcleasing hormone agonist
(19).
Although stromal activity of the postmcnopausal ovary varies and this variation
is assumed to correlate with its endocrine function, few studies have been performed to
corroborate this assumption.
It is now generally accepted that the postmcnopausal ovary produces steroids,
mainly androgens in the form of T and A (20). This finding was confirmed by a previous
study on the endocrine activity of the postmenopausal ovary in 35 patients (1). In the
present study, we investigated the relationship between the morphological state of the
postmcnopausal ovary and its endocrine function. We could not demonstrate a relation
between ovarian vein levels of El and E2 and the degree of stromal hypcrplasia of the
ovaries. This finding stresses that a direct relationship between ovarian morphology,
local estrogen levels, and endomctrial pathology is lacking. From our data it cannot be
concluded that estrogens play a role in the presence of (prc)malignant changes of the
endomctrium. Interestingly, we were able to demonstrate a significant relationship
between the degree of stromal hypcrplasia and the production of androgens (both A and
T). Therefore, it is tempting to speculate that ovarian morphology and consequently
ovarian androgen production play a role in the development of pathological conditions
of the uterine endomctrium. We reported previously that ovarian vein concentrations of
A and T were elevated in women with endomctrial cancer when compared with the
levels determined in women with benign gynecological conditions (21).
The findings of the present study arc not completely in accordance with the results
reported by Lucisano ct al. (22) who found that the ovarian steroid levels of El, E2, and
A, but not T, were significantly increased in ovarian venous blood of patients with
moderate or marked stromal hypcrplasia as compared with the levels in the ovarian vein
of women with ovaries with stromal atrophy (20). The discrepancy with our findings is
difficult to explain. The selection of patients may have played a role. In our study, 15 of
18 patients had endomctrial atypic hyperplasia or endometrial carcinoma. In the study
by Lucisano ct al., 35 of 58 postmcnopausal women had endomctrial pathology. Although
it is tempting to speculate on a causal relationship between ovarian stromal hyperplasia,
elevated androgen concentrations, and endomctrial pathology, one has to face the
possibility that elevated concentrations of androgens in the ovarian venous blood is a
phenomenon primarily associated with the presence of endomctrial carcinoma. Further
studies into this field are warranted.
The small numbers of women in the individual study groups do not allow
conclusions on the relation between time since menopause and ovarian morphology or
on the relation between the different steroids determined. From the present study, we
conclude that the amount of stromal hyperplasia in postmcnopausal ovaries is correlated
with the ovarian vein levels of A and T.
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Abstract
The presence of lutcinizing hormone (LH) receptors, follicle-stimulating hormone
(FSH) receptors, and gonadotrophin-relcasing hormone (GnRH) receptors was studied
in human postmcnopausal ovaries. In ovaries of 10 postmcnopausal women, no FSH
and LH receptors were detected by autoradiography after incubation of tissue slices
with ''M-labclcd hormones. By analysis of FSH, LH and GnRH receptor mRNAs in
ovaries of 7 postmcnopausal women with endomctrial carcinoma, expression of full
length FSH and GnRH receptor mRNA was found using RNasc protection. Expression
of full length LH receptor mRNA was absent, whereas expression of LH receptor mRNA
splice variants 1,2 and 3 was found. We hypothesize that GnRH and GnRH agonists not
only have an indirect effect on postmcnopausal ovarian function (via suppression of LH
and FSH) but also may have a direct effect on postmcnopausal ovarian hormone
production.
Introduction
The gonadotrophins LH and FSH arc produced by the pituitary and are the main
regulators of gonadal function. The production of LH and FSH is under control of the
central nervous system through the secretion of GnRH from the hypothalamus into the
hypothalamo-pituitary portal blood, and of feedback action of gonadal hormones.
LH and FSH act on specific cells in the ovaries. LH stimulates theca and granulosa
cells, whereas FSH stimulates granulosa cells.
Gonadotrophic hormone action is mediated via specific membrane-associated
hormone receptors. These gonadotrophin receptors belong to the family of G protein-
coupled receptors, which interact with intracellular guanidine nucleotide-binding proteins
or G proteins (1 -3). G protein-coupled receptors show general characteristics such as
ligand binding, receptor activation, G protein coupling, intracellular signalling and cellular
desensitization.
There arc various ways of detecting the presence of receptors. The LH-reccptor
has been detected with specific monoclonal antibodies reacting with the extracellular
domain of the LH receptor (4), or by the detection of LH bound to the receptor using
monoclonal antibodies recognising the ß-subunit of LH (5). With the autoradiographic
method using '"I-FSH, '"I-hCG or other LH-like proteins, it is possible to localise FSH
and LH receptors in the ovary (6). The detection of mRNAs encoding for the receptors
of LH, FSH and GnRH can be performed by Northern blot analysis or RNase protection.
The purpose of the present study was to examine the presence of LH and FSH
receptors on different cell types in intact postmcnopausal ovaries by the autoradiographic
method using '-• I-FSH or '^I-hCG. The expression of LH, FSH and GnRH receptor
mRNAs was determined in homogenized postmcnopausal ovaries.
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Material and methods
Autoradiographic method
j In ovaries from ten postmenopausal patients the presence of LH and FSH receptors
was studied by the autoradiographic method using '-M-FSH, or '•• I-hCG. Women were
considered postmenopausal if their last menstrual period had been more than twelve
months before the onset of the study. None of the patients had received oestrogen
replacement therapy for at least six months preceding the investigation. The protocol
used for this study was approved by the hospital ethics committee. All patients signed
an informed consent. The patients underwent uni- or bilateral salpingo-oophorcctomy
for various reasons.
The ovarian specimens were frozen immediately in liquid nitrogen and stored at
-80°C. Sections of 15 urn were sliced at -29°C, using a cryostat microtome and were
collected on gelatin coated object slides kept at 25°C. Object slides were kept at -80°C
until used. Every other section (collected on different object slides) was blown dry,
fixed for 2 minutes in acetone and stained with Hacmatoxylin Eosin (HE). To identify
cellular binding sites for hCG and FSH, sections were encircled with a hydrofobic wax
(Dakopcn, ITK Diagnostics BV, Uithoorn, The Netherlands), washed briefly with buffer
C (lOmM Tris, 5mM MgCl^, 0.1% (w/vv)BSA at a pH of 7.4) and incubated in a
humidified chamber at room temperature for 5 hours with 10 ul of a solution containing
the labelled gonadotrophin (0.05 nM '"I-FSH [NEX-173, NEN Research Product,
Hoofddorp, The Netherlands] or 0.05 nM '"I-hCG [NEX-106, NEN Research Product]
in buffer C) without or with 1 OOOx molar excess of rccombinant human FSH (Org 32489,
Organon, Oss, The Netherlands) or hCG (Prcgnyl, Organon). The slides were washed
twice in cold buffer C for 3 minutes, and 10 times in Milli Q water and completely
dried. A Hypcrfilm-'H (Amcrsham, Den Bosch, The Netherlands) was exposed for 7
days to the slides and developed.
Receptor mRNA detection method
The presence of LH, FSH and GnRH receptors by measuring receptor mRNAs
was performed in homogenized ovaries of seven other postmenopausal patients who
underwent uni- or bilateral salpingo-oophorcctomy because of cndomctrial carcinoma.
As a control, three ovaries obtained from normal cyclic women were used.
Total RNA was isolated using a microscale version of the method described by
Chomczynski and Sacchi (7). The human FSH receptor RNA probe was generated from
a 633 bp fragment cloned in pBluescript corresponding to bp 1306 to 1939 of the cDNA
(8), and the human LH receptor RNA probe from a 350 bp fragment cloned in pBluescript
corresponding to the 5'end of the human LH receptor cDNA (9).
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A human GnRH receptor RNA probe was generated from a 385 bp Hindffl fcDNA
fragment cloned in pBlucscript (10). For the y-actin RNA probe a 130 bp cDNA fragment
in pGEM-4Z was used (11). RNase protection assays of 50 ng total RNA were performed
as described by Baarcnds ct at. (12). y-actin was used as a control for RNA loading. The
relative amount of protected mRNA band was quantified through exposure of the gels
to a phosphor screen (Molecular Dynamics, B & L Systems, Zoctermeer, The Nether-
lands), followed by a calculation of the relative density of the obtained bands using a
phospho-imagcr and Image Quant (Molecular Dynamics) as computer analysis software.
The findings arc shown in arbitrary units, expressed as the ratios between the bands and
the corresponding y-actin values.
Results
Autoradiographic method
Ovarian sections often postmcnopausal women were available for the characteri-
zation of FSH and LH receptors. In the HE stained cryostat sections no follicles were
visible. Incubation of alternate sections with '"I-FSH or '"I-hCG did not result in specific
staining (lOOOx excess of cold FSH or hCG). As a positive control, rat ovarian sections
Normal ovaries PMP ovaries
FSHR LHRfl LHR1 LHR2 LHR3 GnRHR
Fig. /. Expression o/rAe F5///Ü// /engrA receptor ^F5//Ä>. fAe L///Ü// /eng/A receptor (X//Ä
fAe L// receptor .vp/»cf rarian» / ,2 . i (L///J/. L//Ä2. Z.//ÄJ/ a«J fAe GnÄ// receptor
yowwrf Av /Wase profecfi'on earperj'mentt.
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were used resulting in clear labeling of cells of larger follicles with both FSH and hCG,
and of corpora lutea with only hCG.
Receptor mRNA detection method
Results of the RNase protection experiments on control prcmcnopausal ovaries
and on a different set of seven postmcnopausal ovaries arc summarized in Figure 1. The
mean relative expression of the full length FSH receptor in postmcnopausal ovaries was
five times lower than in the control ovaries. Due to the large variation in expression in
the control tissues, no significant difference was found between the expression in both
groups.
The full length LH receptor was just detectable in the prcmcnopausal ovaries, but
expression in the postmcnopausal ovaries was at background level. In contrast, mean
expression of the LH receptor splice variants 1,2, and 3, which all lack the transmembranc
domain, was detected in the postmenopausal ovaries. Finally, the level of expression of
the GnRH receptor was comparable in both groups of ovaries.
Discussion
During the reproductive stage of life, gonadotrophins control the functioning of
theca, granulosa, and luteal cells of the ovary through their interaction with specific
receptors. Specific receptors for LH/hCG and FSH in these cells have been identified
(13-20). Also in human ovarian neoplasms gonadotrophin binding sites for both LH and
FSH have been localized (21). Very little information is available on gonadotrophin
receptor sites in human postmenopausal ovaries.
In this study, we wanted to detect and localize LH and FSH receptors in
postmenopausal ovarian tissue. For this reason we chose for the autoradiographic method
using '"I-FSH or '"I-hCG as radiolabeled ligands. However, we were not able to show
LH and FSH receptors in postmcnopausal ovaries by this method. This was probably
not caused by a lack of sensitivity of the method used because in a control group of
intact rat ovaries, abundant amounts of receptors for both LH and FSH were localized in
granulosa cells. Our results arc in agreement with the results of a study by Vihko and co-
workers on the presence of these receptors in human postmenopausal ovaries (22). These
authors explained their results on basis of the high scrum gonadotrophin levels in
postmenopausal women; a negative correlation was found between scrum levels of LH
and FSH and ovarian LH and FSH receptors. Pcluso and co-workers, however, reported
that binding sites for LH and FSH were localized in the cells of cortical stroma of
postmenopausal ovaries (23). This was confirmed in a study by Nakano and co-workers
(24). In all of these studies the autoradiographic method was used. The reason for the
varying results of these investigations remains unclear.
Another method for measuring the possible presence of LH and FSH receptors is
detecting the presence of LH and FSH receptor messengerRNA (mRNA) by RNase pro-
81
tection analysis. The presence of LH and FSH mRNAs has been found in studies of
ovaries during the reproductive period of life, especially in the granulosa cells of
prcovulatory follicles (25-27). No information exists on the presence of LH and FSH
receptor mRNA in human postmcnopausal ovaries. -
In the present study we could detect the expression of full length FSH mRNa, but
only of splice variants of LH mRNA. Since these splice variants lack essential exons,
they will not be able to convey the LH signal to the inside of the cell.
The presence of GnRH receptor mRNA in human ovaries and in ovaries of cycling
animals has been demonstrated before (28-32). Also in ovarian tumours expression of
GnRH receptor has been found (33). The present study is the first to show expression of
GnRH receptor mRNA in human postmcnopausal ovaries.
In a previous study, we demonstrated that the postmcnopausal ovary produces
significant amounts of A and T (34). We suggested that the production of T by the
postmcnopausal ovary was in part stimulated by the high levels of circulating gona-
dotrophins, because down-regulation of scrum gonadotrophin levels by administration
of a GnRH agonist resulted in a decrease of T production by the postmcnopausal ovary.
Alternatively, because of the detection of GnRH receptor expression in postmcnopausal
ovaries it is possible that the decrease of the production of T in the postmcnopausal
ovary is a result of a direct down-regulation of the GnRH-receptor signalling as a result
of the administration of the GnRH agonist. Imai and co-workers already suggested that
the administration of the GnRH agonist buscrclin to normally cyclic women may exert
a direct inhibitory effect on ovarian steroidogencsis by an action at the gonadal level
(35). Similarly, Brus and co-workers found, in normally cycling women, that high affinity
ovarian GnRH receptors arc present predominantly in ovarian tissue following the LH
surge (36).
In summary, it is concluded that in postmcnopausal ovaries in vivo, steroidogenesis
might be down-regulated by a direct action of high levels of a GnRH agonist. This
observation should be confirmed by in vitro experiments.
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CHAPTER 7
GENERAL DISCUSSION
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The aim of this study was to investigate functional and morphological aspects of
the postmenopausal ovary. The postmcnopausal period of life is receiving much attention
recently. The supplction of oestrogens during the postmcnopausal period appears to
have a positive effect on the prevention of coronary heart disease, osteoporosis and
Alzheimer's disease (1-6). For these reasons, oestrogen replacement therapy in
postmcnopausal women has been advocated. Inactivity of the postmcnopausal ovary
caused by a lack of active follicular growth is held responsible for the hypo-oestrogenic
state in postmcnopausal women. The assumption that a postmcnopausal ovary is inactive
and therefore redundant is not supported by the studies published. However, the results
of these studies are conflicting.
In the present study we have addressed the following questions:
1. Docs poslmcnopausal ovarian hormonal activity exist?
2. If so, to which degree is this activity related to ovarian morphology?
3. Do gonadotrophins still have a regulatory effect on this presumed postmenopausal
ovarian activity?
4. Can gonadotrophin receptors be detected in the postmcnopausal ovary?
The present study differs from other studies on these subjects in that one and the
same group of patients was used to address all four questions mentioned.
The study was performed in postmcnopausal women, all of whom underwent
uni- or bilateral oophorcctomy, with or without hysterectomy. Four patients were excluded
for various reasons (withdrawal of informed consent, inadequate administration of the
GnRH-agonist, two patients with an ovarian malignancy, one of whom had a granulosa-
ccll tumour).
'an Aormo«a/ flc/ivrt_y exis/
To determine if the postmcnopausal ovary has endocrine functions we had to
develop a method to obtain blood from the ovarian veins during operation. The combined
study of hormone concentrations in these ovarian veins, of hormone concentrations in
peripheral veins, and the effect of oophorcctomy on peripheral hormone levels provided
information on the endocrine activity of an ovary. A sampling method was developed
(chapter 2, section I) and shown to be adequate in a patient with a unilateral ovarian
granulosa-ccll tumour (chapter 2, section II). From our study we conclude that the
postmenopausal ovary produces significant amounts of the androgens, A and T. No
oestrogen production was found (chapter 4, section I). This result is compared with the
data from the literature in Table 1, which is the extended Table 1 from chapter 1. Our
results are in agreement with the combined data of Judd ct al. (7) and of Vcrmeulen (8)
on peripheral hormone levels before and after oophorcctomy, and with the in vitro data
of Mattingly et al. (9). Comparison with literature done on ovarian vein levels of steroids
in postmenopausal ovaries yields a less clear picture; especially because a number of
authors did not indicate significance levels for the differences between ovarian and
peripheral venous concentrations. Nevertheless, we conclude that our results on the
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Table 1. Review of the literature concerning postmenopausai ovarian production of oestrone (E1). oestradiol (E2). androstenedtone (A), and testosterone (T)
together with the results of the present study.
ovanan vs peripheral vein serum before vs after oophorectomy
(one group of patients)
before vs after oophorectomy
(din* groups of patents)
in v*ro studies
Mattmglyetal(1969)
Rader et al (1973)
Juddetal(1974)
Juddetal(1974)
Greenblatt et al (1970)
Vermeulenetal(1976)
Juddetal(1976)
Oenneforsetal(19eO)
Longcopeetal(1980)
Lucisanoetal(19S4)
Aimanetal(1986)
Present study (1999)
E1=;E2=
E1T (P<0 05); E2t (P<0 05)
At (ns),Tt(P<0 01)
E2=
AT(ne);Tt(ne)
E1=;E2T(«?)
A= ; TT (S?)
Eit(P<0 01);E2t(P<0.001)
At(P<0 01);Tt(P<0.001)
E1=;E2t(s?)
A=,Tt(s?)
EI-;E>
A t (P<0.001 control group ;
PO.0001 GnRHa-group)
T t (P<0.0001 both control and
GnRHa-group)
U ( P 0 . 0 0 1 ) ; A ; ( P 0 . 0 0 1 )
E1-;E2-
E l i (PO.01 control group)
E2<1 (PO.0I control group)
T l (P<O.(MM)1 control group ;
P-cO.05 GnRHa-group)
A and T producHon
E1«;E2»
Ai (PO.01) ;U(P<0.01)
ESandAproduotton
M>IMl ; • ? • alflnMcanc« unknown
largcsts scries of women reported support the general observation of non-significant
secretion of ocstrogens, whereas both T and A are secreted in significant amounts by
postmcnopausal ovaries.
However, we have to consider that the ovarian veins not only drain the ovary but
also part of the uterus. It is therefore preferable to speak of venous sampling of the
utcro-ovarian venous plexus. If a hormone concentration is increased in an ovarian vein
compared with the peripheral serum levels, this proves ovarian secretion of the hormone.
Another question is whether this ovarian secretion forms also a significant contribution
to the total production of the steroid in the body. Production is the sum of secretion of a
hormone by endocrine glands (ovaries, adrenal glands) together with its peripheral
formation by conversion of precursor steroids. For the calculation of hormone secretion
by a gland it is important to know the blood flow through that organ in 24 hours. No
exact data arc known about the blood flow through a postmcnopausal ovary in 24 hours.
IJaird el al. calculated an ovarian plasma flow of 60 L/day in prcmcnopausal women,
but ovarian plasma flow in postmcnopausal women is probably below 10% ofthat (10).
The secretion of an androgen by the ovary will only influence the peripheral scrum level
ofthat androgen if the ovarian production is really substantial compared with non-ovarian
sources of that same androgen. The peripheral level of T six weeks after operation was
H10nifw*pnlly lowor than tho peripheral 2ov<?J oi"7* bo/ot\? operation. T7u3 iniiicalCd ifltll
the production of T by the postmcnopausal ovary must have been substantial, whereas
this was not the case for A.
It would be interesting to know whether the ovarian vein levels of A and T will
change with postmcnopausal age and with time after menopause. In a group of 680
postmcnopausal women no correlations were found between El, E2, A, and post-
mcnopausal age (11). However, because in that study only peripheral serum hormone
levels were measured, the source of steroid production (i.e. ovarian vs adrenal gland) is
uncertain. By measurement of ovarian vein levels of A and T in 20 postmcnopausal
women we were not able to demonstrate an age related change (chapter 4, section II).
In order to determine whether postmenopausal ovarian androgen production is influenced
by postmenopausal age or time after menopause, a larger group of patients with ovarian
vein sampling should be studied.
In conclusion: The postmenopausal ovary produces significant amounts of A and
T, although only T contributes significantly to its peripheral serum levels. We were
not able to demonstrate a relation between pelvic A and T levels with either
chronological or postmcnopausal age.
//"so, /o wAi'cA rfegree w po.Yfmt'/Jo/?aw.sa/ Aormona/ ac//'v/7v re/o/et/ /o ovar/an
A / ?
Previous studies have been published in which the relationship between ovarian
histology and endomctrium pathology was investigated (12-15). It has been demonstrated
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that the increased risk of endometrial cancer is caused by (1) an increased endogenous
oestrogen production caused by oestrogen producing tumours, (2) the increased peripheral
aromatization of A, such as occurs in obesity, or (3) a prolonged exogenous administration
of oestrogens unopposed by progestational agents (16-19). Several studies have focussed
on the relationship between endogenous ovarian hormone production and endometrial
cancer (7,20). There is one study in which the ovarian morphology has been correlated
with ovarian steroid production by measuring hormone levels in the ovarian veins (21).
This investigation demonstrated significant differences for scrum levels of El, E2, A,
and T between the ovarian and peripheral veins. The ovarian vein levels of El, F2, and
A were significantly higher in ovaries with moderate-severe stromal hyperplasia
compared with those of atrophic ovaries. This difference was not found for T levels.
From our study (chapter 5) it was concluded that the postmcnopausal ovary docs not
produce oestrogens and that only the ovarian vein levels of A and T were significantly
higher in ovaries with moderate-severe stromal hyperplasia compared with atrophic
ovaries. The question arises whether these higher androgen levels play a direct role in
the etiology of endometrial carcinoma. In a related study, we have reported that compared
with women with benign gynaecological conditions, the ovarian vein scrum levels of A
and T were elevated in women with endometrial cancer (22), as was already suggested
by Nagamani et al. (20). It is possible that the higher levels of androgens arc aromatized
in fat tissue to oestrogens, which play a role in the etiology of endometrial cancer.
However, results of immuno-histochemical techniques indicate that also androgen
receptors arc present in the endometrium (23,24). Therefore, the androgens produced
by the ovarian stroma might play a direct ctiological role in endometrial cancer.
Alternatively, it is also possible that the conversion of androgens into oestrogens occurs
locally in the endometrium. Tseng et al. found that the human endometrium can synthesize
oestrogens from T and A at a concentration equal to plasma levels (25). The capacity for
aromatization in neoplastic endometrium is 2-5 times higher than that in normal
endometrium (26), and T also inhibits 17ß-hydroxysteroid dehydrogenase activity
competitively in endometrium, which would result in reduced oxidation of E2 to El,
with accumulation of E2 in endometrial tissue (27).
Future research should focus on the relationship between ovarian morphology,
local androgen levels and carcinoma of the endometrium together with studies
investigating the possible direct proliferative effect of androgens on the endometrium or
the possible proliferative effect of increased local endometrial oestrogen synthesis
resulting from increased aromatasc activity in the endometrium.
In conclusion: The amount of stromal hyperplasia in postmcnopausal ovaries is
correlated with the ovarian vein levels of A and T. Morphological characteristics of
the postmenopausal ovary are correlated with the local (i.e. pelvic) endocrine milieu
and may play a role in the etiology of hormone-dependent diseases of the internal
genitals.
91
Z)o go/jaf/o/ro/7Ä/>js .y//7/ Aave a regM/a/ory e^ fecf on /Httf/wenopausa/ ovar/a/j
The putative regulatory effect of gonadotrophins on ovarian steroid production
was investigated by pituitary down regulation with a single depot-dose of a GnRHa two
weeks before operation. The effects of the administration of human chorionic
gonadotrophin on ovarian steroid secretion (eg oestrogen), was first documented in
postmcnopausal women by Poliak ct al. (28), later followed by studies on the effect of
GnRHa (29,30). Gonadotrophin levels were determined in 17 postmenopausal women
before and after administration of a single depot-dose of the GnRHa triptorelin (chapter
3). A significant decrease of LH and FSH levels in postmenopausal women was obtained
after two weeks.
The effect of administering hCG or GnRHa on circulating peripheral serum
oestrogen and androgen levels has been reported in several studies (8,28,31,32). However,
no studies have been performed in which the possible regulatory effect of gonadotrophins
on ovarian venous hormone levels has been investigated by creating a hypogonadotrophic
state. In our study (chapter 4, section I) we found that T production by the post-
mcnopausal ovary is reduced after suppression of the high levels of circulating
gonadotrophins; the adrenal glands also produce significant amounts of T, but these
organs arc not under gonadotrophic control. The absence of effect on peripheral levels
of A may be due to the relatively large adrenal contribution to the circulating levels of
this steroid.
In conclusion: we demonstrated a significant decrease of LH and FSH serum levels
in postmcnopausal women within two weeks after administration of a single depot-
dose of the CiiiRH agonist triptorelin. The production of T by the postmenopausal
ovary is in part stimulated by the high levels of circulating gonadotrophins.
Can gonaoo/rop/H/i nece/J/ors oe tfe/ec/«/1« f/ie pas/mewopau.ya/ ovary?
Some studies showed an increase in postmcnopausal ovarian steroid production
after the administration of hCG (28,33). Because in our study (chapter 4, section I) a
regulating effect of gonadotrophins was found on the ovarian testosterone production
we expected to find gonadotrophin receptors in postmenopausal ovarian tissue (chapter
6). After incubation of postmcnopausal ovarian tissue slices with '"I-labeled hormones,
no FSH and LH receptors were detected by autoradiography (chapter 6). A method
failure was less likely because rat ovarian sections were used as a control with normal
results for the detection of LH and FSH receptors. Our results were in agreement with
the study by Vihko and co-workers (34).
Using RNasc protection experiments on a different set of postmenopausal ovaries,
full length FSH receptor mRNA was found to be present but -not significantly- lower
compared with prcmcnopausal ovaries. Full length LH receptor mRNA expression was
at background level. However, expression of LH receptor mRNA splice variants 1, 2,
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and 3 was detected in the postmenopausal ovaries. These splice variants lack essential
exons and they will therefore not be able to convey the LH signal to the inside of the
cell.
This is the first study in postmenopausal ovaries in which GnRH mRN A receptor
expression was found using the RNase protection method (chapter 6). It is possible that
the decrease of the production of T in the postmenopausal ovary is a result of a direct
down-regulation of GnRH-receptor signalling as a result of the administration of the
GnRH agonist. In vitro studies will clarify whether the administration of a GnRHa directly
to incubated cultures of postmenopausal ovarian cells will result in a higher testosterone
production by these cells.
In conclusion: GnRH receptor mRN A expression was demonstrated in postmeno-
pausal ovaries by using RNase protection. Probably GnRH and GnRH agonists
not only have an indirect effect on postmenopausal function (via LH and FSH) but
also have a direct effect on postmenopausai hormone production.
From the present investigation we conclude that the postmenopausal ovary is not inactive
in terms of steroid (i.e. predominantly androgen) production. Ovarian testosterone
production is gonadotrophin-driven and contributes significantly to the levels of T in
the circulation. It is therefore tempting to speculate that ovarian T plays a role in post-
menopausal health.
Summary of suggestions for future research ;
* measuring ovarian blood flow in postmenopausal women in order to be able
to calculate ovarian production of the androgens A and T
* studying the influence of postmenopausal age and time after menopause on
the ovarian androgen production by performing ovarian vein sampling in a
larger group of patients
* investigating the relationship between ovarian morphology, local androgen
levels and carcinoma of the endometrium together with studies investigating
the possible direct proliferative effect of androgens on the endometrium or
the possible proliferative effect caused by increased local endometrium oestro-
gen levels as a result of increased aromatase activity in the endometrium
* studying in vitro whether direct administration of GnRHa to cultures of post-
menopausal ovarian cells will result in a higher androgen production by these
cells
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In this study the function of the postmenopausal ovary was investigated. To this
end, peripheral vein blood samples were taken from postmenopausal women who, for
various reasons, had to undergo surgery. The samples were taken two weeks before,
during and after surgery. During surgery, also ovarian vein blood samples were collected.
To attain pituitary down-regulation, a single dose of a GnRH agonist (3.75 mg triptoreline
IM as a depot-dose) was administered to a number of randomly selected patients.
In chapter 2, section I a description is given of how ovarian vein blood was
sampled during surgery. To determine the selectivity of the procedure, the peripheral
and ovarian vein levels of androstencdione in 32 patients were compared. The results
confirm the validity of the test. In virtually all cases, the method to obtain utero-ovarian
blood samples was successful and without complications.
The clinical relevance of the sampling method, described in chapter 2, section II
was accidentally established in the case of a patient with a small granulosa cell carcinoma
in the right ovary. After comparing the peripheral and ovarian vein levels of inhibin, the
former appeared to be in the prcmcnopausal range. In contrast with the left ovarian vein,
the inhibin levels in the right ovarian vein were increased substantially. This finding
made us conclude that inhibin is a potential early marker for granulosa-ccll tumours.
The more so since, although the peripheral scrum inhibin levels in this patient had
obviously changed, this was accompanied by an increase in ocstradiol. We were able to
locate the specific site of inhibin production, i.e. the granulosa-ccll tumour.
There is practically no literature on the effects of GnRHa (gonadotropin releasing
hormone agonist) administration to postmenopausal women. Chapter 3 details the results
of an investigation among seventeen patients into the effects of GnRHa administration
to postmenopausal women. Two weeks after administration, the serum gonadotrophin
levels were suppressed to prcmcnopausal levels. Despite their upward trend, eight weeks
after administering a single depot-dose of the GnRHa, the LH and FSH serum levels
were still substantially lower than before.
Chapter 4, section I explores the endocrine activity of the postmenopausal ovary
and the effect of down-regulation of gonadotrophin secretion. These were studied in a
group of 35 postmenopausal women, to fifteen of whom a single depot-dose of GnRHa
was administered two weeks before surgery. The remaining twenty women served as
controls. The investigation revealed that the postmenopausal ovary produces considerable
amounts of androstencdione (A) and testosterone (T), although oophorectomy was
observed to have a major effect on peripheral serum levels of T only. The high levels of
circulating gonadotrophins are to some degree accountable for the stimulation of T
production although pituitary down-regulation does not altogether eliminate androgenic
activity.
Chapter 4, section II considers the effects of chronological age and time after
menopause on ovarian vein androgen levels. These were examined in (a small group of)
20 postmenopausal patients. On the basis of the results, however, it is not possible to
relate pelvic androstencdione and testosterone levels to either chronological age or time
after menopause.
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In 18 postmenopausal women a possible correlation was studied between the
concentrations of oestrogens and androgens in the ovarian vein, and the ovarian degree
of stromal hypcrplasia. In chapter 5 details of the study are given revealing a connection
between the amount of stromal hypcrplasia in postmenopausal ovaries and the production
of androstenedionc and testosterone. A higher degree of stromal hypcrplasia is
accompanied by an increase in androstenedionc and testosterone concentrations in the
ovarian veins. No relation was found between the concentration of ocstronc/ocstradiol
and the amount of stromal hypcrplasia. It is suggested that morphological characteristics
of the menopausal ovary determine the local endocrine status and may play a role in the
etiology of carcinoma of the endomctrium.
The presence of LH, FSH, and GnRH receptors was studied in postmenopausal
ovaries (chapter 6). In ten postmenopausal ovaries no LH or FSH receptors were found
by autoradiographic detection using '-'I-labclcd hormones. In seven other postmenopausal
ovaries using the RNase protection method, expression of full length FSH and (inRII
receptor mRNA was found. Only expression of splice variants of LH receptor mRNA
were present. It was postulated that GnRH and GnRHa not only have an indirect effect
on postmenopausal ovarian function (via LH and FSH) but also may have a direct effect
on postmenopausal ovarian hormone production.
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Bij dit ondcrzock stond dc functic van hct postmcnopauzaal ovarium ccntraal.
Om dczc tc mctcn werden bij postmenopauzale vrouwen, die om uiteenlopende redencn
ccn operatic mocstcn ondcrgaan, pcrifcrc veneuzc bloedmonstcrs afgenomen, namclijk
twee weken voor, tijdens en na de operatic. Ook werden tijdens de operatie ovariele
vencuze bloedmonstcrs afgenomen. Met hct oog op down-regulatic van de hypofyse
krecg ccn aantal -at random gekozen- paticntcn ccnmalig ecn GnRH agonist tocgediend.
Hoofdstuk 2, sectie I bcschrijft dc mcthodc waarmcc tijdens de operatie ovanccl
blocd wcrd afgenomen. Om dc sclcctiviteit van dc procedure vast te stellen, werden de
pcrifcrc en ovariele scrum spicgcls van androstcendion bij 32 patintcn met elkaar
vergclckcn. Dc validitcit van dc test wcrd bevestigd. Dc mcthodc wcrd in nagenoeg alle
gcvallcn met succcs uitgevoerd en cr traden geen complicatics op.
De klinische rclcvantic van dcze mcthodc van sampling wordt gcillustrccrd aan
ccn paticntc met ccn granulosacclcarcinoom in hct rechter ovarium, bij wie de pcrifcrc
en ovariele metingen van inhibinc met elkaar werden vcrgclekcn (Hoofdstuk 2, sectie
II). Dc pcrifcrc conccntratic van inhibinc bevond zieh in dc premenopauzale range. In
scrum uit de rechter ovariele plexus waren de waarden van inhibinc echter significant
hogcr dan die in dc linker ovariele vencuze plexus. Op grond van dczc bevinding wcrd
vastgesteld dat inhibinc al mogclijk in ccn vrocg stadium kan duiden op dc aanwezighcid
van ccn granulosaceltumor, met name omdat hct bij deze paticnte ging om een
waarnccmbarc verandering (t.o.v. de postmenopauzale normaalwaarden) van de
conccntratic van inhibinc in perifcer blocd zondcr dat dit gepaard ging met ccn vcrhoogd
ocstradiol. Dc pick waar inhibinc wcrd aangcmaakt, namclijk ecn kleine granulosacel-
tumor, wcrd prccics gclokalisccrd.
Er is nog zecr wcinig ondcrzock gcdaan naar dc effecten van tocdicning van ccn
GnRH agonist aan postmenopauzale paticntcn. Hoofdstuk 3 belicht de resultatcn van
ccn ondcrzock hicmaar ondcr 17 postmenopauzale paticnten. Dc patienten kregen een-
malig ecn GnRH agonist (GnRHa) in de vorm van een depot-prcparaat toegediend.
Twee weken na tocdicning werden de effecten gemeten. Hicrbij bleek dat de
gonadotropincwaardc in hct blocd gedaald was cn zieh in dc premenopauzale range
bevond. Acht weken na tocdicning van dc GnRHa vertoonden de LH- en FSH-spiegcls
in hct blocd wcliswaar wedcrom ccn stijgende lijn, maar waren zij nog steeds significant
lager dan dc waarden vöor tocdicning van dc agonist.
Hoofdstuk 4, sectie I bcschrijft een deelondcrzoek bij 35 postmenopauzale
vrouwen naar dc endocricne wcrking van hct postmcnopauzaal ovarium en de invlocd
van down-rcgulatic van dc hypofysc. Van dc dcclncmers kregen vijftien vrouwen twee
weken voor hun operatic ccn ccnmaligc depot-dosis GnRHa. Dc overige twintig vrouwen
fungeerden als controlcgrocp. Uit dit ondcrzoek kwam naar vorcn dat het postmcno-
pauzaal ovarium aanzicnlijkc hocvcclhcden androsteendion (A) en testostcron (T)
sccrctccrt, ofschoon allccn T ccn significant bijdrage levert aan dc T waarden in perifeer
blocd. Dc productie van dcrgclijkc hocvcclhcden T door hct postmenopauzaal ovarium
wordt gestimulccrd door de hogc gonadotropinen Spiegels in de circulatic hocwel down-
rcgulatic van de hypofyse de T productie niet vollcdig onderdrukt.
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Hoofdstuk 4, sectie II brcngt dc rcsultatcn in kaart van ecn Studie bij 20
postmenopauzale paticntcn. Hierbij wcrd gekeken naar dc invlocd van lecftijd en tijd na
de menopauze op de androgene waarden in ovarieel blocd. Er kon (in deze kleine groep)
geen verband tussen dcze twee grootheden en dc androstcendion- en tcstostcronwaarden
in het bekken worden aangetoond.
In hoofdstuk 5 wordt cen ondcrzock beschrcven naar ecn eventucel verband tussen
de concentraties van ocstrogencn en androgenen in hct ovarie'le blocd en de mate van
stroma hyperplasie van hct ovarium. Hct ondcrzock wcrd uitgevoerd bij achtticn
postmenopauzale vrouwen. Geconcludeerd wcrd dat dc mate van stroma hyperplasic in
hct postmenopauzaal ovarium gclijkc trcd houdt met dc productic van androstcendion
en testosteron: hoc mccr stroma hyperplasie, des tc hogcr de concentraties androstcendion
en testosteron in het ovaricle bloed. Er wcrd geen rclatic aangctroflcn tussen dc oestron
of oestradiol concentraties en dc mate van stromale hyperplasie. Er wordt gesuggcrccrd
dat morfologischc karaktcristicken van hct postmenopauzaal ovarium hct lokale
cndocricnc milieu bcinvlocdcn en dat zij ecn rol spclcn in dc ctiologic van hct endo-
mctriumcarcinoom.
Een Studie naar dc aanwezighcid van LH, FSH en GnRH rcccptorcn in postmeno-
pauzale ovaria is beschrcven in hoofdstuk 6. Met hct gebruiken van '"I gclabcldc hor-
monen werden gcen LH en FSH rcccptorcn aangetoond in ticn postmenopauzale ovaria.
In zeven andere postmenopauzale ovaria werd met bchulp van dc RNasc protection
mcthodc exprcssic van 'full length' FSH receptor mRNA en van GnRH receptor mRNA
aangetoond. Van hct LH receptor mRNA werden allccn 'splice variants' aangctrolTcn.
Mogclijk hebben GnRH of GnRHa nict allccn ecn indirect effect op dc functic van het
postmenopauzaal ovarium (via LH en FSH), maar hebben zij ook ecn direct effect op dc
hormoonproduktic van hct postmenopauzaal ovarium via dczc GnRH rcccptorcn.
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ADDENDUM 1
Patienten folder samengcsteld samen met het
patienten-voorlichtingsbureau van het
De Wever-Ziekcnhuis te Hccrlcn.
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ONDERZOEK NAAR DE FUNCTIE VAN
EIERSTOKKEN NA DE OVERGANG
INLEIDING
Hicrstokkcn spclcn in hct lcvcn van dc vrouw ccn belangrijkc rol. Met name in de
vruchtbarc levcnsfasc zijn zij onontbccrlijk. Naast hct maken van citjes, produccrcn zij
ook hormoncn. ,....-•...
Dc lecftijd waarin ccn vrouw in dc overgang komt is afhankclijk van dc
hocvcclhcid citjes die zieh in dc cicrstokken bevinden. Wannccr dc citjes in de eicrstokken
op zijn, raakt ccn vrouw in dc overgang. Men hccfl altijd aangenomen dat cicrstokken
na dc overgang nauwclijks nog hormoncn maken en dus net zo goed kunnen worden
verwijderd. Dc laatstc tijd verschijnen er echter studies die vermelden dat cierstokken
na de overgang zeker nog hormoncn maken en dus acticf zijn. Wclkc hormoncn zij
maken en hoevcel is nog onduidclijk.
DOEL VAN IIET ONDERZOEK
Dc afdcling Gynaccologic/Obstctric van hct Dc Wevcr-Zickenhuis is 1 januari
1990 gestart met ccn ondcrzock naar dc functic van cicrstokken na de overgang.
Hct docl van dit ondcrzoek is om op ecn nieuwe manier de functic van dc
cicrstokken na dc overgang zo vollcdig mogclijk in kaart tc brcngen. Wij hopen hicrmec
ccn zinvolle bijdragc tc levcren aan hct medisch vraagstuk of eierstokken na dc overgang
nog ccn functic hebben of nict.
WIE KUNNEN MEEDOEN?
Alleen vrouwen, die na dc ovcrgang zijn en om ccn medische reden aan baarmoeder
en eicrstokken mocten worden gcoperccrd, kunnen aan dit ondcrzoek medoen.
WAT HOUDT HET ONDERZOEK IN?
Hct ondcrzock bestaat uit:
* Hct samen met de arts invullcn van een vragenlijst
* Hct ccnmalig via ccn injectic tocdicnen van ccn hormoonpreparaat waardoor de pro-
ductic van hormoncn door dc eicrstokken wordt stilgelcgd. Dit hormoonpreparaat
wordt vaak gcbruikt bij dc bchandcling van vrouwen met vruchtbaarhcidsproblemcn;
bijwerkingen komen nict of nauwclijks voor.
* Enkclc malen wordt blocd afgenomen om hierin hormoonspiegels te kunnen bepalen.
Dczc controles worden vrijwcl gehcel in hct routine-bloedonderzock ingepast, waar-
door cr zo min mogclijk hoeft tc worden geprikt.
* Na dc operatic zullcn dc eicrstokken door de patholoog-anatoom worden onderzocht
om dc producticplaats van dc hormonen tc kunnen vaststcllcn.
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CONSEQUENTIES VOOR DE PATIENT
Zoals reeds vermeid, kunnen aan dit ondcrzock allccn patienten mccdocn die na
de overgang geopercerd worden aan baarmocder en eierstokken. Er kan pas met
ondcrzoek worden begonnen als de patient hiervoor schriftelijk haar toestemming beert
gegeven. Twee weken na de injeetie vindt de operatic plaats. Bij cen deel van de patienten
zal het gaan om een kwaadaardige aandoening van de baarmoeder. Bij hen zal de
noodzaak tot operatic worden gesteld na ecn curettagc. In de praktijk bedraagt de wachtti jd
tussen curettage en operatic minimaal twee weken. Door dit ondcrzock zal deze periode
niet worden verlcngd. Bckend is overigens dat cen kwaadaardig gczwcl van de
baarmoeder dermate langzaam grocit dat cen tijdsduur van 2 weken tussen diagnose en
therapic medisch gezien gecn conscqucntics heeft.
VOORUITGANG DANKZIJ ONDERZOEK
Dit ondcrzock heeft voor u pcrsoonlijk geen nut, met andere woorden: u wordt er
niet beter van. Door deel te nemen aan dit onderzock levert u wcl cen bijdragc aan het
oplossen van een medisch vraagstuk.
Vooruitgang in de genceskunde is allccn mogelijk dankzij onderzocken waaraan
patienten deelnemen. Wij denken met dit ondcrzock cen nuttige bijdragc aan de
geneeskunde te kunnen leveren cn aan de gynaecologie in het bijzondcr. Het ondcrzock
is bovendien zodanig opgezet dat het voor u nauwclijks belastend is.
VERANTWOORDELIJK
Het onderzock wordt verricht onder verantwoordclijkheid van de maatschap
gynaecologie van het De Wever-Ziekenhuis door dr M.J. Heineman, gynaecoloog cn
door A. V. Sluijmer, arts-assistent in opleiding tot gynaecoloog.
Dokter Sluijmer zal patienten, die aan het onderzoek dcelnemen, bcgclcidcn waar
het dit onderzoek betreft. Van te voren heeft hij cen uitgebreid gesprck met u waarin u
uw vragen kwijt kunt. Uw eigen gynaecoloog blijft verder, wat uw aandoening betreft,
voor u zorgen.
Deelname aan dit onderzoek wordt enorm op prijs gesteld maar is geheel
vrijblijvend. Wij nemen het u niet kwalijk wanneer u niet wenst deel tc nemen. Natuurlijk
zal dit geen gevolgen hebben voor uw bchandcling.
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IINFORMED CONSENT
Ondergetekende geeft hierbij haar schriftelijke toestenming voor deelname aan het
onderzoek getiteld 'Ageing Gonads", een onderzoek iaar de functie van eierstokken
na de overgang.
Zij verklaart tevens kennis te hebben genomen van d> patientenbrochure en mondeling
voldoende te zijn ingelicht over het onderzoek.
Naam: - -
Adres:
Geboortedatum:
Handtekening:
ADDENDUM 2
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PROJEKT AGEING GONADS
IDENTIFICATIENUMMER,
GROEPSNUMMER
Identlflcatle
* identificaticnummer
* ziekenhuis
* naam
* gebuortcdatum
* nationaliteit
* postcode
orMaclilMlMiii en Miami
I. Voorneschiedcnis
tr. circulatorius :
medicatie
* hypertensic
medicatie
* tr. respiratonus :
medicatie
* tr. digestivus :
medicatie
* tr.urogenitalis :
medicatie
* CZS :
medicatie
* overige :
medicatie
' operaties
2. Alcemene anamnese
* datum :_
* tr. circulatorius :
medicatie :
* hypertensie :
medicatie
* tr. respiratorius :
medicatie
* tr. digestivus :
medicatie :
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* tr. urogenitalis
medicatie
•czs
medicatie
• overige
medicatie
* roken
* alcohol
* medicatie
Obstetrische anamnese:
* datum
* gravida
* para
* abortus/mola
sig/dag
2. Gynaecologische anamnese:
* datum
* maligniteit
lokatie
diagnose
therapie
* menarche
* cyclus premenopauzaal
* menopauze
* huidige klacht
bloedverlies
therapie
fluor
therapie
pruritus
therapie
pijn
therapie
endocrinologie
therapie
* begin huidige klacht
ja /nee
dgn
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• datum
* uitstrijkje
datum
uitslag
*aanvullend onderzoek
echoscopie
laparoscopie
cystoscopie
rectosigmoidoscopie
overige
Pre-operatief onderzoek
1. Lichamclijk onderzoek:
• datum
• lengte
* gewicht
• blocddruk
2. Blocdondcrzoek:
•Hb
•Ht
•BSE
•Alat
• Kreat
• Kalium
3. UrineonjdoaKkj
4. ECG:
5. X-thorax:
Bevindineen per- en postoperatief
1. Curettafe:
• datum
• sondelengte
• cervixcurettage
• corpuscurettage
• cavum
•PA
: / /
: ja /nee
: / /
: ja /nee
/ /
m
. k«
/
, mmol/L
0.
mm/uur
mmol/L
mmol/L
, mmol/L
/ /
cm
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4MMLMXW 1
2. Decapcptvl*:
• datum
• bijwerkingen
3. Operatic:
4. Postoperatief:
* datum
• gewicht
• soon operatie
• Cytologie buikvocht
* complicaties
bloedverlies
laesies
* complicaties
infecties
haematoom/nabloed.
trombo-embolieen
wonddehiscentie
overige
* gewicht na 6 weken
/ /
. tea
ja/nee
ja /nee
• • • • • • • • ' • ' • • • • • • *
ja / nee
/ kg
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